,,,COVID-19 Interventions,,SOP for Data Entry (Version 1),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,Product,,Product Information,,,,,,,,,,,Milestones,,Pre-Clinical Development Milestones,,,Manufacturing Milestones,Regulatory Milestones,Clinical Development Milestones,,,Regulatory Milestones,ON THE MARKET,,Highest Status Ongoing Clinical Study (see clinical study tab for more studies),,,,,,,,,,,,,,,,
ID,Source?,Product Name - Preferred,Product Name - Chemical,Product Name - Brand,Sponsor,Intervention Type,Indication,Molecule Type,Therapeutic Approach,New/Repurposed,Funding/Manufacturing/Research/Other Partners,Country,Status,Notes,,Current Status,,Discovery Started,Pre-Clinical Studies Started,Lead Selection Finalized,Clinical Batch Finalized,IND or Equivalent Approval Finalized,Phase 1 Started,Phase 2 Started,Phase 3 Started,NDA or equivalent Approval Finalized,,,Phase,Condition or Disease,Number of Participants,Accepts Healthy Subjects,# of Sites,Sites Locations,Study Start Date,Primary Completion DAte,Study Completion Date,CTG Identifier,How to participate,,Data Entry Owner,Date Entry Performed,Data Entry Update Owner,Date Update Performed,
1,No,mRNA-1273,mRNA-1273,,Moderna; National Institute of Allergy and Infectious Diseases,Vaccine - Prophylactic,COVID-19,Nucleic acid based therapies/vaccines,Unknown,New,CEPI,United States,Ongoing,mRNA-based vaccine,,Phase 1,,1/11/2020,SKIPPED,1/13/2020,2/7/2020,3/4/2020,3/16/2020,,,,,,1,COVID-19,45,,2,Kaiser Permanente Washington Health Research Institute - Seattle - Washington; Emory Children's Center - Decatur - Georgia,3/16/2020,6/1/2021,6/1/2021,NCT04283461,https://corona.kpwashingtonresearch.org/,,Mats,3/27/2020,,,
1,Yes,https://www.nih.gov/news-events/news-releases/nih-clinical-trial-investigational-vaccine-covid-19-begins,https://www.nih.gov/news-events/news-releases/nih-clinical-trial-investigational-vaccine-covid-19-begins,,https://www.nih.gov/news-events/news-releases/nih-clinical-trial-investigational-vaccine-covid-19-begins,https://www.nih.gov/news-events/news-releases/nih-clinical-trial-investigational-vaccine-covid-19-begins,https://www.nih.gov/news-events/news-releases/nih-clinical-trial-investigational-vaccine-covid-19-begins,https://www.nih.gov/news-events/news-releases/nih-clinical-trial-investigational-vaccine-covid-19-begins,https://www.nih.gov/news-events/news-releases/nih-clinical-trial-investigational-vaccine-covid-19-begins,https://www.nih.gov/news-events/news-releases/nih-clinical-trial-investigational-vaccine-covid-19-begins,https://www.nih.gov/news-events/news-releases/nih-clinical-trial-investigational-vaccine-covid-19-begins,https://www.nih.gov/news-events/news-releases/nih-clinical-trial-investigational-vaccine-covid-19-begins,https://www.nih.gov/news-events/news-releases/nih-clinical-trial-investigational-vaccine-covid-19-begins,https://www.nih.gov/news-events/news-releases/nih-clinical-trial-investigational-vaccine-covid-19-begins,,https://www.nih.gov/news-events/news-releases/nih-clinical-trial-investigational-vaccine-covid-19-begins,https://www.nih.gov/news-events/news-releases/nih-clinical-trial-investigational-vaccine-covid-19-begins,https://www.modernatx.com/modernas-work-potential-vaccine-against-covid-19,https://www.modernatx.com/modernas-work-potential-vaccine-against-covid-19,https://www.modernatx.com/modernas-work-potential-vaccine-against-covid-19,https://www.modernatx.com/modernas-work-potential-vaccine-against-covid-19,https://www.modernatx.com/modernas-work-potential-vaccine-against-covid-19,https://www.modernatx.com/modernas-work-potential-vaccine-against-covid-19,,,,,,https://clinicaltrials.gov/ct2/show/NCT04283461?term=coronavirus+vaccine&draw=2,,https://clinicaltrials.gov/ct2/show/NCT04283461?term=coronavirus+vaccine&draw=1,https://clinicaltrials.gov/ct2/show/NCT04283461?term=coronavirus+vaccine&draw=2,https://clinicaltrials.gov/ct2/show/NCT04283461?term=coronavirus+vaccine&draw=3,https://clinicaltrials.gov/ct2/show/NCT04283461?term=coronavirus+vaccine&draw=4,https://clinicaltrials.gov/ct2/show/NCT04283461?term=coronavirus+vaccine&draw=5,https://clinicaltrials.gov/ct2/show/NCT04283461?term=coronavirus+vaccine&draw=6,https://clinicaltrials.gov/ct2/show/NCT04283461?term=coronavirus+vaccine&draw=7,,https://corona.kpwashingtonresearch.org/,,,,,,
2,No,Novavax Vaccine,Novavax Vaccine,,Novavax Inc.; Emergent BioSolutions Inc.,Vaccine - Prophylactic,COVID-19,Subunit Vaccines,Other,New,CEPI,United States,Ongoing,not totally clear that it is prophylactic vaccine. P1 expected late spring,,Pre-Clinical Testing,,,03/10/2020,,,,,,,,,,,,,,,,,,,,,,James,4/2/2020,,,
2,Yes,https://investors.emergentbiosolutions.com/news-releases/news-release-details/emergent-biosolutions-signs-agreement-novavax-manufacture?field_nir_news_date_value[min]=,https://investors.emergentbiosolutions.com/news-releases/news-release-details/emergent-biosolutions-signs-agreement-novavax-manufacture?field_nir_news_date_value[min]=,,https://investors.emergentbiosolutions.com/news-releases/news-release-details/emergent-biosolutions-signs-agreement-novavax-manufacture?field_nir_news_date_value[min]=,https://investors.emergentbiosolutions.com/news-releases/news-release-details/emergent-biosolutions-signs-agreement-novavax-manufacture?field_nir_news_date_value[min]=,https://ir.novavax.com/news-releases/news-release-details/novavax-awarded-funding-cepi-covid-19-vaccine-development,https://ir.novavax.com/news-releases/news-release-details/novavax-awarded-funding-cepi-covid-19-vaccine-development,,https://ir.novavax.com/news-releases/news-release-details/novavax-awarded-funding-cepi-covid-19-vaccine-development,https://ir.novavax.com/news-releases/news-release-details/novavax-awarded-funding-cepi-covid-19-vaccine-development,https://ir.novavax.com/news-releases/news-release-details/novavax-awarded-funding-cepi-covid-19-vaccine-development,,,,https://ir.novavax.com/news-releases/news-release-details/novavax-awarded-funding-cepi-covid-19-vaccine-development,,,https://ir.novavax.com/news-releases/news-release-details/novavax-awarded-funding-cepi-covid-19-vaccine-development,,,,,,,,,,,,,,,,,,,,,,,,,,
3,No,BNT162,BNT162,,Pfizer Inc.; BioNTech SE,Vaccine - Prophylactic,COVID-19,Nucleic acid based therapies/vaccines,Other,New,Polymun,Germany,Ongoing,Expect clinical testing in late april. Note this drug is also being developed in china with fosun pharma. Assumed this is in discovery as no explicit statements aboit preclinical found,,Pre-Clinical Testing,,,03/16/2020,,,,,,,,,,,,,,,,,,,,,,James,4/2/2020,,,
3,Yes,BNT162,BNT162,,https://www.pfizer.com/news/press-release/press-release-detail/pfizer_and_biontech_to_co_develop_potential_covid_19_vaccine,https://www.pfizer.com/news/press-release/press-release-detail/pfizer_and_biontech_to_co_develop_potential_covid_19_vaccine,https://www.pfizer.com/news/press-release/press-release-detail/pfizer_and_biontech_to_co_develop_potential_covid_19_vaccine,https://www.pfizer.com/news/press-release/press-release-detail/pfizer_and_biontech_to_co_develop_potential_covid_19_vaccine,https://www.pfizer.com/news/press-release/press-release-detail/pfizer_and_biontech_to_co_develop_potential_covid_19_vaccine,https://www.pfizer.com/news/press-release/press-release-detail/pfizer_and_biontech_to_co_develop_potential_covid_19_vaccine,https://biontech.de/,https://biontech.de/,https://www.pfizer.com/news/press-release/press-release-detail/pfizer_and_biontech_to_co_develop_potential_covid_19_vaccine,https://www.fiercebiotech.com/biotech/weeks-to-go-to-covid-19-vaccine-trial-biontech-lands-135m-deal-and-advances-pfizer-talks,,https://biontech.de/node/159,,,https://biontech.de/node/159,,,,,,,,,,,,,,,,,,,,,,,,,,
4,No,Imperial College London Vaccine,Imperial College London Vaccine,,Imperial College London,Vaccine - Prophylactic,COVID-19,Nucleic acid based therapies/vaccines,Other,New,,United Kingdon,Ongoing,Expect clinical testing in summer,,Pre-Clinical Testing,,,02/10/2020,,,,,,,,,,,,,,,,,,,,,,James,4/2/2020,,,
4,Yes,,,,https://www.imperial.ac.uk/news/196313/in-pictures-imperial-developing-covid19-vaccine/,https://www.imperial.ac.uk/news/196313/in-pictures-imperial-developing-covid19-vaccine/,https://www.imperial.ac.uk/news/196313/in-pictures-imperial-developing-covid19-vaccine/,https://www.imperial.ac.uk/news/196313/in-pictures-imperial-developing-covid19-vaccine/,Other,https://www.imperial.ac.uk/news/196313/in-pictures-imperial-developing-covid19-vaccine/,,,,https://www.imperial.ac.uk/news/196313/in-pictures-imperial-developing-covid19-vaccine/,,https://www.imperial.ac.uk/news/196313/in-pictures-imperial-developing-covid19-vaccine/,,,https://www.imperial.ac.uk/news/196313/in-pictures-imperial-developing-covid19-vaccine/,,,,,,,,,,,,,,,,,,,,,,,,,,
5,No,INO-4800,INO-4800,CELLECTRA®,Inovio Pharmaceuticals Inc.; Beijing Advaccine Biotechnology.; US Department of Defense.; Ology Bioservices Inc.,Vaccine - Prophylactic,COVID-19,Nucleic acid based therapies/vaccines,Monoclonal antibodies,New,"US DoD, Bill and Melinda Gates Foundation, Coalition for Epidemic Prepardness Innovations Funding",United States,Ongoing,,,Pre-Clinical Testing,,1/23/2020,,,03/24/2020,,04/01/2020,,,,,,1,COVID-19,,,,United States,,,,,,,Joseph Malinao,04/02/2020,,,
5,Yes,INO-4800,INO-4800,,https://www.precisionvaccinations.com/vaccines/ino-4800-dna-coronavirus-vaccine,,COVID-19,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
6,No,Ad26 SARS-CoV-2,,Ad26 SARS-CoV-2,Janssen,Vaccine - Prophylactic,COVID-19,Gene therapies,Other,New,BARDA,Belgium,Ongoing,Expect clinical testing no later than fall 2020,,Pre-Clinical Testing,,,03/31/2020,,,,,,,,,,,,,,,,,,,,,,James,4/2/2020,,,
6,Yes,https://www.hhs.gov/about/news/2020/03/30/hhs-accelerates-clinical-trials-prepares-manufacturing-covid-19-vaccines.html,https://www.hhs.gov/about/news/2020/03/30/hhs-accelerates-clinical-trials-prepares-manufacturing-covid-19-vaccines.html,,https://milkeninstitute.org/sites/default/files/2020-03/Covid19%20Tracker%20NEW3-30-20.pdf,https://www.hhs.gov/about/news/2020/03/30/hhs-accelerates-clinical-trials-prepares-manufacturing-covid-19-vaccines.html,COVID-19,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5609467/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5609467/,https://www.hhs.gov/about/news/2020/03/30/hhs-accelerates-clinical-trials-prepares-manufacturing-covid-19-vaccines.html,https://www.hhs.gov/about/news/2020/03/30/hhs-accelerates-clinical-trials-prepares-manufacturing-covid-19-vaccines.html,,https://www.hhs.gov/about/news/2020/03/30/hhs-accelerates-clinical-trials-prepares-manufacturing-covid-19-vaccines.html,https://www.hhs.gov/about/news/2020/03/30/hhs-accelerates-clinical-trials-prepares-manufacturing-covid-19-vaccines.html,,https://www.sciencemag.org/news/2020/03/1-billion-bet-pharma-giant-and-us-government-team-all-out-coronavirus-vaccine-push,,,https://www.sciencemag.org/news/2020/03/1-billion-bet-pharma-giant-and-us-government-team-all-out-coronavirus-vaccine-push,,,,,,,,,,,,,,,,,,,,,,,,,,
7,No,Sanofi Vaccine,Sanofi Vaccine,,Sanofi; BARDA,Vaccine - Prophylactic,COVID-19,Subunit Vaccines,Other,Repurposed-Not Approved,BARDA,France,Ongoing,they are repurposing vaccines that have been preclinically tested for SARS - hence I have put the current status as preclinical,,Pre-Clinical Testing,,,02/18/2020,,,,,,,,,,,,,,,,,,,,,,James,4/2/2020,,,
7,Yes,,,,http://www.news.sanofi.us/2020-02-18-Sanofi-joins-forces-with-U-S-Department-of-Health-and-Human-Services-to-advance-a-novel-coronavirus-vaccine,,COVID-19,http://www.news.sanofi.us/2020-02-18-Sanofi-joins-forces-with-U-S-Department-of-Health-and-Human-Services-to-advance-a-novel-coronavirus-vaccine,http://www.news.sanofi.us/2020-02-18-Sanofi-joins-forces-with-U-S-Department-of-Health-and-Human-Services-to-advance-a-novel-coronavirus-vaccine,http://www.news.sanofi.us/2020-02-18-Sanofi-joins-forces-with-U-S-Department-of-Health-and-Human-Services-to-advance-a-novel-coronavirus-vaccine,http://www.news.sanofi.us/2020-02-18-Sanofi-joins-forces-with-U-S-Department-of-Health-and-Human-Services-to-advance-a-novel-coronavirus-vaccine,https://www.google.com/search?q=sanofi+pasteur+headquarters&rlz=1C5CHFA_enGB854GB854&oq=sanofi+pastuer+head&aqs=chrome.1.69i57j0l7.7080j1j9&sourceid=chrome&ie=UTF-8,https://www.sanofi.com/en/media-room/press-releases/2020/2020-02-18-16-00-00,https://www.sanofi.com/en/media-room/press-releases/2020/2020-02-18-16-00-00,,,,,https://www.sanofi.com/en/media-room/press-releases/2020/2020-02-18-16-00-00,,,,,,,,,,,,,,,,,,,,,,,,,,
8,No,Regeneron Therapeutic,,Regeneron Therapeutic,Regeneron; HHS,Therapeutic,COVID-19,Protein-based (including monoclonal antibodies),Monoclonal antibodies,New,,United States,Ongoing,Plan to start human trials in summer 2020. Technique was previously used to develop successful REGN-EB3 ebola treatment.,,Discovery,,2/4/2020,,,,,,,,,,,,,,,,,,,,,,,Matthew,4/1/2020,,,
8,Yes,https://investor.regeneron.com/index.php/news-releases/news-release-details/regeneron-announces-expanded-collaboration-hhs-develop-antibody,,https://investor.regeneron.com/index.php/news-releases/news-release-details/regeneron-announces-expanded-collaboration-hhs-develop-antibody,https://investor.regeneron.com/index.php/news-releases/news-release-details/regeneron-announces-expanded-collaboration-hhs-develop-antibody,https://investor.regeneron.com/index.php/news-releases/news-release-details/regeneron-announces-expanded-collaboration-hhs-develop-antibody,https://investor.regeneron.com/index.php/news-releases/news-release-details/regeneron-announces-expanded-collaboration-hhs-develop-antibody,https://investor.regeneron.com/index.php/news-releases/news-release-details/regeneron-announces-expanded-collaboration-hhs-develop-antibody,https://investor.regeneron.com/index.php/news-releases/news-release-details/regeneron-announces-expanded-collaboration-hhs-develop-antibody,https://investor.regeneron.com/index.php/news-releases/news-release-details/regeneron-announces-expanded-collaboration-hhs-develop-antibody,,https://investor.regeneron.com/index.php/news-releases/news-release-details/regeneron-announces-expanded-collaboration-hhs-develop-antibody,https://newsroom.regeneron.com/index.php/news-releases/news-release-details/regeneron-announces-important-advances-novel-covid-19-antibody,https://www.regeneron.com/covid19,,https://newsroom.regeneron.com/index.php/news-releases/news-release-details/regeneron-announces-important-advances-novel-covid-19-antibody,,https://investor.regeneron.com/index.php/news-releases/news-release-details/regeneron-announces-expanded-collaboration-hhs-develop-antibody,,,,,,,,,,,,,,,,,,,,,,,,,,,
9,No,Vaxart Vaccine,Vaxart Vaccine,Vaxart Vaccine,Vaxart,Vaccine - Prophylactic,COVID-19,Subunit Vaccines,,New,Emergent,United States,Ongoing,Oral tablet. Recombinant vaccine. Plan to initiate Phase I trial in second half of 2020.,,Discovery,,3/18/2020,,,,,,,,,,,,,,,,,,,,,,,Matthew,3/30/2020,,,
9,Yes,Vaxart Vaccine,Vaxart Vaccine,,https://investors.vaxart.com/news-releases/news-release-details/vaxart-announces-it-entered-agreement-emergent-biosolutions,https://investors.vaxart.com/news-releases/news-release-details/vaxart-announces-it-entered-agreement-emergent-biosolutions,https://investors.vaxart.com/news-releases/news-release-details/vaxart-announces-it-entered-agreement-emergent-biosolutions,https://investors.vaxart.com/news-releases/news-release-details/vaxart-announces-it-entered-agreement-emergent-biosolutions,,https://investors.vaxart.com/news-releases/news-release-details/vaxart-announces-it-entered-agreement-emergent-biosolutions,https://investors.vaxart.com/news-releases/news-release-details/vaxart-announces-it-entered-agreement-emergent-biosolutions,,https://investors.vaxart.com/news-releases/news-release-details/vaxart-announces-it-entered-agreement-emergent-biosolutions,https://investors.vaxart.com/news-releases/news-release-details/vaxart-announces-it-entered-agreement-emergent-biosolutions,,https://investors.vaxart.com/news-releases/news-release-details/vaxart-announces-it-entered-agreement-emergent-biosolutions,,https://investors.vaxart.com/news-releases/news-release-details/vaxart-announces-it-entered-agreement-emergent-biosolutions,,,,,,,,,,,,,,,,,,,,,,,,,,,
10,No,University of Queensland Vaccine,University of Queensland Vaccine,,University of Queensland,Vaccine - Prophylactic,COVID-19,Subunit Vaccines,,New,CEPI; The Queensland Government; Paul Ramsay Foundation; a2 Milk Company,Australia,Ongoing,Plans for clinical trials in July in Queensland.,,Discovery,,1/24/2020,,,,,,,,,,,,,,,,,,,,,,,Matthew,3/30/2020,,,
10,Yes,University of Queensland Vaccine,University of Queensland Vaccine,,https://www.uq.edu.au/news/article/2020/01/race-develop-coronavirus-vaccine,https://www.uq.edu.au/news/article/2020/01/race-develop-coronavirus-vaccine,https://www.uq.edu.au/news/article/2020/01/race-develop-coronavirus-vaccine,https://www.uq.edu.au/news/article/2020/01/race-develop-coronavirus-vaccine,,https://www.uq.edu.au/news/article/2020/01/race-develop-coronavirus-vaccine,https://stories.uq.edu.au/news/2020/17m-shot-in-the-arm-for-uq-covid-19-vaccine-research/index.html,https://www.uq.edu.au/news/article/2020/01/race-develop-coronavirus-vaccine,https://stories.uq.edu.au/news/2020/17m-shot-in-the-arm-for-uq-covid-19-vaccine-research/index.html,https://stories.uq.edu.au/news/2020/17m-shot-in-the-arm-for-uq-covid-19-vaccine-research/index.html,,https://stories.uq.edu.au/news/2020/17m-shot-in-the-arm-for-uq-covid-19-vaccine-research/index.html,,https://www.uq.edu.au/news/article/2020/01/race-develop-coronavirus-vaccine,,,,,,,,,,,,,,,,,,,,,,,,,,,
11,No,VIDO-InterVac Vaccine Candidate,VIDO-InterVac Vaccine Candidate,,International Vaccine Centre; University of Saskatchewan,Vaccine - Prophylactic,COVID-19,Unknown,Unknown,New,Canadian Federal Government,Canada,Ongoing,,,Pre-Clinical Testing,,02/01/2020,ONGOING,,,,,,,,,,,,,,,,,,,,,,Arshy,03/29/2020,,,
11,Yes,https://www.technologynetworks.com/tn/news/12m-awarded-for-new-covid-19-vaccine-manufacturing-efforts-332506,https://www.technologynetworks.com/tn/news/12m-awarded-for-new-covid-19-vaccine-manufacturing-efforts-332506,,,https://www.cbc.ca/news/health/coronavirus-covid-19-vido-intervac-saskatchewan-vaccine-1.5508114?__vfz=medium%3Dsharebar,COVID-19,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
12,No,ChAdOx1 nCoV-19,ChAdOx1 nCoV-19,,Jenner Institute; Oxford Vaccine Group,Vaccine - Prophylactic,COVID-19,Subunit Vaccines,Unknown,New,University of Oxford,United Kingdom,Ongoing,,,Phase 1,,,,,,,03/20/2020,,,,,,1,COVID-19,510,Yes,,,,,,,,,Arshy,03/29/2020,,,
12,Yes,ChAdOx1,ChAdOx1,https://economictimes.indiatimes.com/news/international/world-news/oxford-university-begins-enrolling-over-500-volunteers-for-coronavirus-vaccine-trial/articleshow/74864754.cms,https://www.ovg.ox.ac.uk/news/covid-19-vaccine-development,https://www.clinicaltrials.gov/ct2/show/NCT04324606,COVID-19,,,,,,,,,,,,,,,,,,,,,,https://www.jackfm.co.uk/news/oxfordshire-news/oxford-uni-clinical-trials-for-covid-19-vaccine-could-begin-next-month/,,,,,,,,,,,,,,,,
13,No,NIV Pune Vaccine Candidate,NIV Pune Vaccine Candidate,,National Institute of Virology-Pune,Vaccine - Prophylactic,COVID-19,Unknown,Unknown,New,,India,Ongoing,,,Discovery,,,,,,,,,,,,,,,,,,,,,,,,,Arshy,03/29/2020,,,
13,Yes,https://www.livemint.com/news/india/covid-19-india-becomes-5th-country-globally-to-isolate-virus-strain-11584102221498.html,https://www.livemint.com/news/india/covid-19-india-becomes-5th-country-globally-to-isolate-virus-strain-11584102221498.html,,,,COVID-19,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
14,No,,,,Chinese Center for Disease Control and Prevention; Tongji University School of Medicine; Stermirna Therapeutics Co. Ltd,Vaccine - Prophylactic,COVID-19,Nucleic acid based therapies/vaccines,Unknown,New,Stermirna Therapeutics Co. Ltd,China,Ongoing,Animal Testing,,Pre-Clinical Testing,,01/24/2020,02/10/2020,,,,,,,,,,,,,,,,,,,,,,Zain,04/01/2020,,,
14,Yes,,,,http://www.xinhuanet.com/english/2020-02/10/c_138771569.htm,http://www.xinhuanet.com/english/2020-02/10/c_138771569.htm,http://www.xinhuanet.com/english/2020-02/10/c_138771569.htm,http://www.xinhuanet.com/english/2020-02/10/c_138771569.htm,http://www.xinhuanet.com/english/2020-02/10/c_138771569.htm,http://www.xinhuanet.com/english/2020-02/10/c_138771569.htm,http://www.xinhuanet.com/english/2020-02/10/c_138771569.htm,http://www.xinhuanet.com/english/2020-02/10/c_138771569.htm,http://www.xinhuanet.com/english/2020-02/10/c_138771569.htm,http://www.xinhuanet.com/english/2020-02/10/c_138771569.htm,,http://www.xinhuanet.com/english/2020-02/10/c_138771569.htm,,http://www.xinhuanet.com/english/2020-02/10/c_138771569.htm,http://www.xinhuanet.com/english/2020-02/10/c_138771569.htm,,,,,,,,,,,,,,,,,,,,,,,,,,
15,No,DelNS1-SARS-CoV2-RBD LAIV,DelNS1-SARS-CoV2-RBD LAIV,University of Hong Kong Vaccine,University of Hong Kong,Vaccine - Prophylactic,COVID-19,Whole-pathogen vaccines,,New,CEPI; Xiamen University; Changchun-Baike; Hualan-Bio; Beijing Wantai; Sinovac; CNBG,China,Ongoing,Live-attenuated vaccine. Plans for clinical trials in July. Proof of concept testing done using MeRS-CoV and various animal models.,,Pre-Clinical Testing,,,,,,,,,,,,,,,,,,,,,,,,,Matthew,3/30/2020,,,
15,Yes,DelNS1-SARS-CoV2-RBD LAIV,DelNS1-SARS-CoV2-RBD LAIV,,https://fightcovid19.hku.hk/hku-state-key-laboratory-for-emerging-infectious-diseases-joins-global-effort-to-develop-covid-19-vaccine/,https://www.hku.hk/press/news_detail_20788.html,https://www.hku.hk/press/news_detail_20788.html,https://www.hku.hk/press/news_detail_20788.html,,https://www.hku.hk/press/news_detail_20788.html,https://www.hku.hk/press/news_detail_20788.html,https://www.hku.hk/press/news_detail_20788.html,https://www.hku.hk/press/news_detail_20788.html,https://www.hku.hk/press/news_detail_20788.html,,https://www.hku.hk/press/news_detail_20788.html,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
16,No,,,,CureVac AG,Vaccine - Prophylactic,COVID-19,Nucleic acid based therapies/vaccines,Unknown,New,CEPI,Germany,Ongoing,Not named yet; 2 products currently undergoing animal studies; plan to start a clinical trial in early summer,,Pre-Clinical Testing,,,,,,,,,,,,,,,,,,,,,,,,,Okezi,04/01/2020,,,
16,Yes,https://www.curevac.com/our-pipeline,,,https://www.curevac.com/news/curevac-focuses-on-the-development-of-mrna-based-coronavirus-vaccine-to-protect-people-worldwide,,COVID-19,,,,https://www.curevac.com/our-pipeline,,,https://www.youtube.com/watch?v=1ZMWJJyoK7A,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
17,No,Ad5-nCoV,Ad5-nCoV,,CanSino Biologics Inc.,Vaccine - Prophylactic,COVID-19,Gene therapies,Other,New,Institute of Biotechnology-Academy of Military Medical Sciences-PLA of China; Jiangsu Province Centers for Disease Control and Prevention; Hubei Provincial Center for Disease Control and Prevention; Tongji Hospital,China,Ongoing,"Vaccine candidate is genetically engineered with the replication-defective adenovirus type 5 as the vector to express SARS-CoV-2 spike protein; Immunogenic action; Current study is assessing evaluate the safety, reactogenicity and immunogenicity; Active but not recruiting",,Phase 1,,,,,,Yes,03/16/2020,,,No,,,1,COVID 19,108,Yes,1,Hubei Provincial Center for Disease Control and Prevention - Wuhan - Hubei China,03/16/2020,12/30/2020,12/20/2020,,Not recruiting,,Okezi,04/01/2020,,,
17,Yes,Ad5-nCoV,Ad5-nCoV,,https://clinicaltrials.gov/ct2/show/NCT04313127?term=ad5-ncov&draw=2&rank=1,,COVID-19,,,,https://clinicaltrials.gov/ct2/show/NCT04313127?term=ad5-ncov&draw=2&rank=1,,,https://www.bioworld.com/articles/433791-china-approves-first-homegrown-covid-19-vaccine-to-enter-clinical-trials  https://www.youtube.com/watch?v=1ZMWJJyoK7A,,,,,,,,,https://clinicaltrials.gov/ct2/show/NCT04313127?term=ad5-ncov&draw=2&rank=1,,,,,,https://clinicaltrials.gov/ct2/show/NCT04313127?term=ad5-ncov&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04313127?term=ad5-ncov&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04313127?term=ad5-ncov&draw=2&rank=1,,https://clinicaltrials.gov/ct2/show/NCT04313127?term=ad5-ncov&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04313127?term=ad5-ncov&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04313127?term=ad5-ncov&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04313127?term=ad5-ncov&draw=2&rank=1,,,,,,,,,
18,No,,,,GeoVax Labs Inc.,Vaccine - Prophylactic,COVID-19,Unknown,Unknown,New,BravoVax,United States,Ongoing,Using existing vaccine platform called GV-MVA-VLP; 3 candidates have been identified; animal trials soon to begin,,Discovery,,,,,,,,,,,,,,,,,,,,,,,,,Okezi,04/01/2020,,,
18,Yes,https://www.geovax.com/news/geovax-progresses-in-coronavirus-covid-19-vaccine-development-program,,https://www.geovax.com/news/geovax-progresses-in-coronavirus-covid-19-vaccine-development-program,https://www.geovax.com/news/geovax-progresses-in-coronavirus-covid-19-vaccine-development-program,,COVID-19,,,,,,,https://www.geovax.com/technology-pipeline/pipeline-summary,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
19,No,INO-4700,INO-4700,,Inovio Pharmaceuticals Inc.; GeneOne Life Science,Vaccine - Prophylactic,COVID-19,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
19,Yes,INO-4700,INO-4700,,,,COVID-19,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
20,No,,,,Medicago,Vaccine - Prophylactic,COVID-19,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
20,Yes,,,,,,COVID-19,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
21,No,NasoVax Analog (Not Currently Specified),NasoVax Analog (Not Currently Specified),NasoVAX,Altimmune,Vaccine - Prophylactic,COVID-19,Nucleic acid based therapies/vaccines,Unknown,Repurposed-Approved,Altimmune,United Sates,Ongoing,Repurposing NasoVax Platform (Recombinant intranasal delivery) for Covid19 Vaccine,,Pre-Clinical Testing,,02/26/2020,,,,,08/01/2020,,,,,,,COVID-19,,,,,,,,,,,Joseph Malinao,04/02/2020,,,
21,Yes,https://www.precisionvaccinations.com/vaccines/nasovax-influenza-vaccine,,https://www.precisionvaccinations.com/vaccines/nasovax-influenza-vaccine,https://ir.altimmune.com/news-releases/news-release-details/altimmune-completes-first-development-milestone-toward-single,,COVID-19,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
22,No,Avian Coronavirus Infectious Bronchitis Virus (IBV) vaccine,Avian Coronavirus Infectious Bronchitis Virus (IBV) vaccine,IBV,MIGAL Research Institute,Vaccine - Prophylactic,COVID-19,Whole-pathogen vaccines,Unknown,Repurposed-Not Approved,"Israel Innovation Authority,  Health Ministry and the Headquarters of the National Digital Israel Initiative",Israel,Ongoing,Adaption of Avian CoronaVirus Infectious Bronchitis Virus Vaccine for Human Use,,Phase 1,,02/27/2020,,,,,,,,,,,,,,,,,,,,,,,Joseph Malinao,04/02/2020,,,
22,Yes,Avian Coronavirus Infectious Bronchitis Virus (IBV) vaccine,Avian Coronavirus Infectious Bronchitis Virus (IBV) vaccine,,https://www.trialsitenews.com/israel-government-announces-13m-covid-19-research-funds-while-migals-claims-a-covid-19-breakthrough/,,COVID-19,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
23,No,TNX-1800,TNX-1800,,Tonix Pharmaceuticals,Therapeutic,COVID-19,Protein-based (including monoclonal antibodies),,New,,United States,Ongoing,,,Discovery,,,,,,,,,,,,,,,,,,,,,,,,,Anusha Joshi,4/1/2020,,,
23,Yes,https://www.tonixpharma.com/,https://www.tonixpharma.com/,,,,COVID-19,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
24,No,Recombinant subunit vaccine,Recombinant subunit vaccine,S-Trimer,Clover Biopharmaceuticals,Vaccine - Prophylactic,COVID-19,Nucleic acid based therapies/vaccines,,New,Glaxosmithkline,China,Ongoing,,,Pre-Clinical Testing,,,,,,,,,,,,,,,,,,,,,,,,,Anusha Joshi,4/1/2020,,,
24,Yes,https://www.bioworld.com/articles/433055-clover-produces-subunit-vaccine-candidate-s-trimer-for-coronavirus,https://www.bioworld.com/articles/433055-clover-produces-subunit-vaccine-candidate-s-trimer-for-coronavirus,,,,COVID-19,,,,,,,,,https://www.who.int/blueprint/priority-diseases/key-action/novel-coronavirus-landscape-ncov.pdf?ua=1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
25,No,Linear DNA Vaccine,Linear DNA Vaccine,,Applied DNA Sciences; Takis Biotech,Vaccine - Prophylactic,COVID-19,Nucleic acid based therapies/vaccines,Other,New,Applied DNA Sciences; Takis Biotech,United States; Rome - Italy,Ongoing,PCR produced linear DNA vaccine,,Pre-Clinical Testing,,,3/18/2020,,,,,,,,,,,,,,,,,,,,,,Azmi,4/1/2020,,,
25,Yes,Linear DNA Vaccine,Linear DNA Vaccine,,https://adnas.com/coronavirus-preclinical-trials-italy-ministry-health/,,COVID-19,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
26,No,NanoFlu,,NanoFlu,Novavax,Vaccine - Prophylactic,Other,Subunit Vaccines,Other,New,Novavax; Emergent BioSolutions Inc; CEPI,United States,Ongoing,recombinant quadrivalent seasonal influenza vaccine using hemagglutinin (HA) protein nanoparticles,,Manufacturing,,,,,,,,,,,,,3,Seasonal Flu/Influenza,2562,Yes,19,,,,3/24/2020,,,,Azmi,4/1/2020,,,There is another being produced by novavax that is pre-phase1 specific for Covid-19 (http://ir.novavax.com/news-releases/news-release-details/novavax-awarded-funding-cepi-covid-19-vaccine-development) - this will need a separate row to populate.
26,Yes,,,,http://ir.novavax.com/news-releases/news-release-details/novavax-nanoflu-achieves-all-primary-endpoints-phase-3-clinical,,COVID-19,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
27,No,,,,Predictive Oncology,Vaccine - Prophylactic,COVID-19,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
27,Yes,,,,,,COVID-19,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
28,No,,,,Integral Molecular,Vaccine - Prophylactic,COVID-19,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
28,Yes,,,,,,COVID-19,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
29,No,,,,AJ Vaccines,Vaccine - Prophylactic,COVID-19,Protein-based (including monoclonal antibodies),Other,New,,,Ongoing,Using modern antigen technology,,Discovery,,,,,,,,,,,,,,,,,,,,,,,,,Zain,04/01/2020,,,
29,Yes,,,,https://ajvaccines.com/news/,https://ajvaccines.com/news/,https://ajvaccines.com/news/,https://ajvaccines.com/news/,https://ajvaccines.com/news/,https://ajvaccines.com/news/,,,https://ajvaccines.com/news/,https://ajvaccines.com/news/,,https://ajvaccines.com/news/,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
30,No,remdesivir,remdesivir,,Gilead Sciences Inc,Therapeutic,COVID-19,Small molecule,Antiviral drugs-not specified,Repurposed-Not Approved,Gilead Sciences,United States,Ongoing,Other trials undertaken by NIAD-USA; INSERM-France; China Japanese friendship hospital; No of study is increasing rapidly,,Phase 3,,,,,,,,,03/15/2020,No,No,,3,COVID 19,600,No,41,"Kaiser Permanente Los Angeles Medical Center - Los Angeles - California; Hoag Memorial Hospital Presbyterian - Newport Beach - California; Stanford Hospital - Stanford - California; University of Chicago - Chicago - Illinois; Brigham & Women's Hospital and Harvard Medical School - Boston - Massachusets; Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center - Lagrangeville - New York; Jamaica Hospital Medical Center - Jamaica - New York; Danbury Hospital - Lagrangeville - New York; Providence Portland Medical Center - Portland - Oregon; Providence St. Vincent Medical Center - Portland - Oregon; The Miriam Hospital - Providence - Rhode Island; Baylor University Medical Center - Dallas - Texas; Houston Methodist Hospital - Houston - Texas; Providence Medical Research Center - Everett - Washington;  Swedish Center for Comprehensive Care - Seattle - Washington; MultiCare Tacoma General Hospital - Tacoma - Washington; Klinikum rechts der Isar der TU Munchen, Klinik und Poliklinik Innere Medizin 2 - Munich - Germany; Prince of Wales Hospital - Hong Kong - Hong Kong; Princess Margaret Hospital - Hong Kong - Hong Kong; Queen Mary Hospital - Hong Kong - Hong Kong; Azienda Ospedaliero Universitaria di Parma - Parma - Islamic Republic of Iran; ASST degli Spedali Civili di Brescia - Brescia - Italy; ASST di Cremona - Azienda Socio Sanitaria Territor - Cremona - Italy; ASST Fatebenefratelli Sacco - Milano - Italy; UOC Malattie Infettive e Tropicali, Azienda Ospedaliera di Padova - Padova PD - Italy;  Malattie Infettive I, Fondazione IRCCS Policlinico San Matteo - Pavia - Italy; Kyungpook National University Hospital - Daegu - Republic of Korea; Seoul Medical Center - Seoul - Republic of Korea; National Medical Center - Seoul - Korea; National University Hospital - Singapore - Singapore; Singapore General Hospital - Singapore - Singapore; National Centre for Infectious Diseases - Tan Tock Seng Hospital - Singapore - Singapore; Hospital Clinic de Barcelona - Barcelona - Spain; Hospital Universitario Cruces - Bizakaia - Spain; Hospital Universitario La Paz - Madrid - Spain; Hopitaux Universitaires de Genève - Genève 14 - Switzerland; Ospedale Regionale di Locarno La Carità - Lugano - Switzerland; Universitätsspital Zürich - Zürich - Switzerland; Kaohsiung Veterans General Hospital - Kaohsiung - Taiwan; China Medical University Hospital- Taichung - Taiwan; National Taiwan University Hospital - Taipei City -Taiwan",03/15/2020,05/2020,,,Contact staff at Gilead Clinical Study Information Center 1-833-445-3230 (GILEAD-0) GileadClinicalTrials@gilead.com,,Okezi,04/01/2020,,,
30,Yes,remdesivir,remdesivir,,https://www.gilead.com/purpose/advancing-global-health/covid-19,,COVID-19,,,,,,,https://www.gilead.com/purpose/advancing-global-health/covid-19/remdesivir-clinical-trials,,,,,,,,,,,https://clinicaltrials.gov/ct2/show/NCT04292730,,,,https://clinicaltrials.gov/ct2/show/NCT04292730,https://clinicaltrials.gov/ct2/show/NCT04292730,https://clinicaltrials.gov/ct2/show/NCT04292730,,https://clinicaltrials.gov/ct2/show/NCT04292730,https://clinicaltrials.gov/ct2/show/NCT04292730,https://clinicaltrials.gov/ct2/show/NCT04292730,,,,https://clinicaltrials.gov/ct2/show/NCT04292730,,,,,,
31,No,lopinavir; ritonavir,lopinavir; ritonavir,Kaletra; Aluvia,AbbVie,Therapeutic,COVID-19,Small molecule,Antiviral drugs-antiretrovirals,Repurposed-Approved,AbbVie,Multiple,Ongoing,Unclear what to do with this one - abbvie is not the sponsor but is the manufacturer of the drug. Some studies are published: https://www.nejm.org/doi/pdf/10.1056/NEJMoa2001282?articleTools=true; https://www.medrxiv.org/content/10.1101/2020.03.19.20038984v1.full.pdf. Note that for the highest study there were multiple phase 4 so I picked the largest one that had alrady started recruiting,,?Phase 4,,,,,,,,,,,,,4,2019-nCoV,400,No,1,Wuhan - China,02/01/2020,06/01/2020,07/01/0202,,https://www.clinicaltrials.gov/ct2/show/NCT04255017?term=lopinavir+ritonavir&cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&phase=3&draw=2&rank=2,,James,04/02/2020,,,
31,Yes,https://milkeninstitute.org/sites/default/files/2020-03/Covid19%20Tracker%20NEW3-30-20.pdf,https://milkeninstitute.org/sites/default/files/2020-03/Covid19%20Tracker%20NEW3-30-20.pdf,https://www.abbvie.com/content/dam/abbvie-dotcom/uploads/PDFs/factsheet-coronavirus-030420.pdf,https://milkeninstitute.org/sites/default/files/2020-03/Covid19%20Tracker%20NEW3-30-20.pdf,https://www.nejm.org/doi/pdf/10.1056/NEJMoa2001282?articleTools=true,COVID-19,https://www.drugbank.ca/drugs/DB01601; https://www.drugbank.ca/drugs/DB01601,https://www.kaletra.com/,https://www.drugbank.ca/drugs/DB01601; https://www.drugbank.ca/drugs/DB01601,https://www.abbvie.com/content/dam/abbvie-dotcom/uploads/PDFs/factsheet-coronavirus-030420.pdf,,,,,,,,,,,,,,,,,,https://www.clinicaltrials.gov/ct2/show/NCT04255017?term=lopinavir+ritonavir&cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&phase=3&draw=2&rank=2,,,,,,,,,,,,,,,,
32,No,Sarilumab,Sarilumab,Kevzara,Regeneron; Sanofi,Therapeutic,COVID-19,Protein-based (including monoclonal antibodies),Nonspecific anti-inflammatory and immunosuppressive drugs,Repurposed-Approved,,Unites States,Ongoing,,,Phase 3,,,,,,,,03/16/2020,03/16/2020,,,,3,Covid-19,400,No,57,"If anyone else has done, copy accross",03/16/2020,03/16/2021,03/16/2021,,https://www.clinicaltrials.gov/ct2/show/NCT04315298,,James,04/02/2020,,,
32,Yes,https://www.drugbank.ca/drugs/DB11767,https://www.drugbank.ca/drugs/DB11767,https://www.drugbank.ca/drugs/DB11767,http://www.news.sanofi.us/2020-03-16-Sanofi-and-Regeneron-begin-global-Kevzara-R-sarilumab-clinical-trial-program-in-patients-with-severe-COVID-19,http://www.news.sanofi.us/2020-03-16-Sanofi-and-Regeneron-begin-global-Kevzara-R-sarilumab-clinical-trial-program-in-patients-with-severe-COVID-19,COVID-19,https://www.drugbank.ca/drugs/DB11767,https://newsroom.regeneron.com/news-releases/news-release-details/regeneron-and-sanofi-begin-global-kevzarar-sarilumab-clinical,https://www.drugbank.ca/drugs/DB11767,,https://www.google.com/search?rlz=1C5CHFA_enGB854GB854&sxsrf=ALeKk022og2HFqxgB2OGNk6Vdmns2VRRhQ%3A1585861871624&ei=71SGXuTZJYKvggfAjrv4BA&q=regeneron+&oq=regeneron+&gs_lcp=CgZwc3ktYWIQAzIICAAQgwEQkQIyBAgAEEMyBQgAEIMBMgUIABCDATIFCAAQgwEyBQgAEIMBMgIIADICCAAyBQgAEIMBMgUIABCDAToECAAQRzoECCMQJzoFCAAQkQI6BwgAEBQQhwJQ2U1Y2ltgp1xoAHABeACAAYYBiAGSB5IBAzYuM5gBAKABAaoBB2d3cy13aXo&sclient=psy-ab&ved=0ahUKEwikjZXs08roAhWCl-AKHUDHDk8Q4dUDCAs&uact=5,https://clinicaltrials.gov/ct2/show/NCT04315298?term=kevzara&cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&draw=2,,,https://clinicaltrials.gov/ct2/show/NCT04315298?term=kevzara&cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&draw=2,,,,,,,,https://clinicaltrials.gov/ct2/show/NCT04315298?term=kevzara&cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04315298?term=kevzara&cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&draw=2&rank=1,,,,https://www.clinicaltrials.gov/ct2/show/NCT04315298,https://www.clinicaltrials.gov/ct2/show/NCT04315298,https://www.clinicaltrials.gov/ct2/show/NCT04315298,https://www.clinicaltrials.gov/ct2/show/NCT04315298,,https://www.clinicaltrials.gov/ct2/show/NCT04315298,https://www.clinicaltrials.gov/ct2/show/NCT04315298,https://www.clinicaltrials.gov/ct2/show/NCT04315298,,,https://www.clinicaltrials.gov/ct2/show/NCT04315298,,James,04/03/2020,,,
33,No,hydroxychloroquine,hydroxychloroquine,,Numerous. University of Minnesota; University of Oxford; IHU-Méditerranée Infection and others; World Health Organization SOLIDARITY trial (chloroquine); New York State Department of Health (hydroxychloroquine with zithromax),Vaccine - Prophylactic,COVID-19,Small molecule,Antimalarial drugs,Repurposed-Approved,,NA,Ongoing,,,?Phase 4,,,,,,,,,,,,,4,COVID 19,800,No,Not listed,Not listed,04/06/2020,11/06/2020,11/06/2020,,https://www.clinicaltrials.gov/ct2/show/NCT04330495?term=hydroxychloroquine&cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&phase=3&draw=2&rank=2,,James,04/04/2020,,,
33,Yes,hydroxychloroquine,hydroxychloroquine,,https://milkeninstitute.org/sites/default/files/2020-03/Covid19%20Tracker%20NEW3-30-20.pdf,https://www.cdc.gov/coronavirus/2019-ncov/hcp/therapeutic-options.html; https://www.npr.org/sections/coronavirus-live-updates/2020/03/31/824572119/clinical-trials-set-to-determine-if-anti-malaria-drug-effective-against-covid-19,COVID-19,https://www.drugbank.ca/drugs/DB01611,https://www.drugbank.ca/drugs/DB01612,https://www.drugbank.ca/drugs/DB01613,,,,,,,,,,,,,,,,,,,https://www.clinicaltrials.gov/ct2/show/NCT04330495?term=hydroxychloroquine&cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&phase=3&draw=2&rank=2,https://www.clinicaltrials.gov/ct2/show/NCT04330495?term=hydroxychloroquine&cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&phase=3&draw=2&rank=3,https://www.clinicaltrials.gov/ct2/show/NCT04330495?term=hydroxychloroquine&cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&phase=3&draw=2&rank=4,https://www.clinicaltrials.gov/ct2/show/NCT04330495?term=hydroxychloroquine&cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&phase=3&draw=2&rank=5,https://www.clinicaltrials.gov/ct2/show/NCT04330495?term=hydroxychloroquine&cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&phase=3&draw=2&rank=6,https://www.clinicaltrials.gov/ct2/show/NCT04330495?term=hydroxychloroquine&cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&phase=3&draw=2&rank=7,https://www.clinicaltrials.gov/ct2/show/NCT04330495?term=hydroxychloroquine&cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&phase=3&draw=2&rank=8,https://www.clinicaltrials.gov/ct2/show/NCT04330495?term=hydroxychloroquine&cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&phase=3&draw=2&rank=9,https://www.clinicaltrials.gov/ct2/show/NCT04330495?term=hydroxychloroquine&cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&phase=3&draw=2&rank=10,,https://www.clinicaltrials.gov/ct2/show/NCT04330495?term=hydroxychloroquine&cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&phase=3&draw=2&rank=11,,,,,,
35,No,TJ003234,TJ003234,TJM2,I-Mab Biopharma,Therapeutic,ARDS,Protein-based (including monoclonal antibodies),Monoclonal antibodies,Repurposed-Not Approved,,China,Ongoing,AntiBody against GM-CSF. Previously passed a phase 1 trial. INDs submitted for phase II clinical trials in China USA and South Korea.,,Phase 1,,,,,,,3/18/2019,,,,,,,,,,,,,,,,,,Matthew,4/1/2020,,,
35,Yes,TJ003234,TJ003234,http://www.i-mabbiopharma.com/en/article-491.aspx,http://www.i-mabbiopharma.com/en/article-491.aspx,http://www.i-mabbiopharma.com/en/article-491.aspx,http://www.i-mabbiopharma.com/en/article-491.aspx,http://www.i-mabbiopharma.com/en/article-491.aspx,http://www.i-mabbiopharma.com/en/article-491.aspx,https://clinicaltrials.gov/ct2/show/NCT03794180,,http://www.i-mabbiopharma.com/en/article-491.aspx,https://apnews.com/Globe%20Newswire/bd107410eacfaa7143eb9ec954e11c70,https://apnews.com/Globe%20Newswire/bd107410eacfaa7143eb9ec954e11c70,,https://apnews.com/Globe%20Newswire/bd107410eacfaa7143eb9ec954e11c70,,,,,,,https://clinicaltrials.gov/ct2/show/NCT03794180,,,,,,,,,,,,,,,,,,,,,,
36,No,AT-100,AT-100,,Airway Therapeutics,Therapeutic,COVID-19,Protein-based (including monoclonal antibodies),Other,Repurposed-Not Approved,,United States,Ongoing,Recombinant surfactant protein developed to treat bronchopulmonary dysplatia. No timeline for clinical trials.,,Pre-Clinical Testing,,,,,,,,,,,,,,,,,,,,,,,,,Matthew,4/1/2020,,,
36,Yes,AT-100,AT-100,,https://www.airwaytherapeutics.com/at-100/,https://www.airwaytherapeutics.com/airway-therapeutics-announces-filing-with-nih-to-evaluate-at-100-as-a-therapy-for-novel-coronavirus/,https://www.airwaytherapeutics.com/airway-therapeutics-announces-filing-with-nih-to-evaluate-at-100-as-a-therapy-for-novel-coronavirus/,https://www.airwaytherapeutics.com/airway-therapeutics-announces-filing-with-nih-to-evaluate-at-100-as-a-therapy-for-novel-coronavirus/,https://www.airwaytherapeutics.com/at-100/,https://www.airwaytherapeutics.com/at-100/,,https://www.airwaytherapeutics.com/airway-therapeutics-announces-filing-with-nih-to-evaluate-at-100-as-a-therapy-for-novel-coronavirus/,https://www.airwaytherapeutics.com/airway-therapeutics-announces-filing-with-nih-to-evaluate-at-100-as-a-therapy-for-novel-coronavirus/,https://www.airwaytherapeutics.com/airway-therapeutics-announces-filing-with-nih-to-evaluate-at-100-as-a-therapy-for-novel-coronavirus/,,https://www.airwaytherapeutics.com/airway-therapeutics-announces-filing-with-nih-to-evaluate-at-100-as-a-therapy-for-novel-coronavirus/,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
37,No,TZLS-501,TZLS-501,,Tiziana Life Sciences,Therapeutic,COVID-19,Protein-based (including monoclonal antibodies),Other,New,Tiziana Life Sciences; Novimmune,United Kingdom,Ongoing,,,,,,,,,,,,,,,,,,,,,,,,,,,,Arshy,03/29/2020,,,
37,Yes,TZLS-501,TZLS-501,,https://www.marketwatch.com/story/uk-biotech-tiziana-life-sciences-says-its-tzls-501-may-be-of-use-in-treating-coronavirus-2020-03-11,,COVID-19,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
38,No,OYA1,OYA1,,OyaGen,Therapeutic,COVID-19,Small molecule,Antiviral drugs-broad spectrum,Repurposed-Not Approved,OyaGen,United States,Ongoing,,,Pre-Clinical Testing,,,,,,,,,,,,,,,,,,,,,,,,,Arshy,03/29/2020,,,
38,Yes,OYA1,OYA1,https://www.biospace.com/article/releases/oyagen-inc-announces-a-compound-in-development-with-broad-antiviral-activity-against-coronaviruses-including-sars-cov-2/,,,COVID-19,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
39,No,BPI-002,BPI-002,,BeyondSpring Inc,Therapeutic,COVID-19,Small molecule,Antiviral drugs-broad spectrum,Repurposed-Not Approved,BeyondSpring Inc,United States,Ongoing,Also being considered as a vaccine adjuvant to stimulate long term immunity; Very little information is available on development stages - A patent has been filed for it by the company but it is not clear what that translates to; Information in column T was seen on just one website,,Pre-Clinical Testing,,,03/13/2020,,,,,,,No,,,,,,,,,,,,,,,Okezi,04/02/2020,,,
39,Yes,BPI-002,BPI-002,,https://www.biospace.com/article/releases/beyondspring-files-for-patent-protection-on-bpi-002-for-the-treatment-of-viral-infections-including-covid-19/,,COVID-19,,,,https://www.beyondspringpharma.com/otherpipeline/index.aspx,,,https://www.biospace.com/article/releases/beyondspring-files-for-patent-protection-on-bpi-002-for-the-treatment-of-viral-infections-including-covid-19/,,,,,https://adisinsight.springer.com/drugs/800049541,,,,,,,https://www.beyondspringpharma.com/pipelineoverview/index.aspx,,,,,,,,,,,,,,,,,,,
40,No,NP-120 (Ifenprodil),NP-120 (Ifenprodil),,Algernon Pharmaceuticals,Therapeutic,ARDS,Protein-based (including monoclonal antibodies),Other,Repurposed-Not Approved,Cascade chemistry,Canada,Ongoing,Therapeutic approach - receptor antagonist; Drug originally evaluated for treatment of Idiopathic Pulmonary Fibrosis,,Phase 2,,,Completed,,,,,06/2020,,,,,2,Idiopathic Pulmonary Fibrosis,20,No,,,06/2020,03/2021,06/2021,,"Contact study staff Nancy Stewart, Ph.D. 204-928-7905 nstewart@gvicds.com",,Okezi,04/02/2020,,,
40,Yes,NP-120 (Ifenprodil),NP-120 (Ifenprodil),,https://algernonpharmaceuticals.com/ipf-np-120/,,ARDS,,,,,,,,,,,,,,,,,https://clinicaltrials.gov/ct2/show/NCT04318704?term=ifenprodil&draw=2&rank=2,,,,,,,,,,,https://clinicaltrials.gov/ct2/show/NCT04318704?term=ifenprodil&draw=2&rank=2,https://clinicaltrials.gov/ct2/show/NCT04318704?term=ifenprodil&draw=2&rank=2,https://clinicaltrials.gov/ct2/show/NCT04318704?term=ifenprodil&draw=2&rank=2,,https://clinicaltrials.gov/ct2/show/NCT04318704?term=ifenprodil&draw=2&rank=2,,,,,,
41,No,APN01,APN01,,University of British Columbia; APEIRON Biologics,Therapeutic,COVID-19,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
41,Yes,APN01,APN01,,,,COVID-19,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
42,No,Brilacidin Tetrahydrochloride,Brilacidin Tetrahydrochloride,Brilacidin,Innovation Pharmaceuticals,Therapeutic,COVID-19,Small molecule,Antibiotics and antiparasitics,Repurposed-Not Approved,Innovation Pharamaceuticals,United States,Ongoing,,,Pre-Clinical Testing,,03/01/2020,,,,,,,,,,,,,,,,,,,,,,,Joseph Malinao,04/02/2020,,,
42,Yes,Brilacidin,Brilacidin,https://static1.squarespace.com/static/5715352e20c647639137f992/t/5e5c0bbea72c2f71ab0978ee/1583090668780/IPIX+Brilacidin+Defensin+Mimetics+-+COVID-19+Overview+March+1+2020+update.pdf,,,COVID-19,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
43,No,leronlimab,leronlimab,,CytoDyn,Therapeutic,COVID-19,Protein-based (including monoclonal antibodies),Monoclonal antibodies,Repurposed-Approved,RedChip companies,United States,Ongoing,Patient treatment underway via Emergency IND; Phase 2 trial protocol filed,,Phase 2,,,,,,IND,,,,,,,,,75,No,,,,,,,,,Anusha Joshi,4/1/2020,,,
43,Yes,leronlimab,leronlimab,,,,COVID-19,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
44,No,Novel Viral Inhibitor,Novel Viral Inhibitor,BTX-025,BIOXYTRAN,Therapeutic,COVID-19,Small molecule,Antiviral drugs-not specified,New,Bioxytran,United States,Ongoing,Novel galectin inhibitor for use in COVID-19. Currently pre-clinical.,,Discovery,,,03/24/2020,,,,,,,,,,,,,,,,,,,,,,Azmi,4/1/2020,,,
44,Yes,Novel Viral Inhibitor,Novel Viral Inhibitor,,https://www.globenewswire.com/news-release/2020/03/24/2005534/0/en/Bioxytran-Licenses-Novel-Viral-Inhibitor-for-COVID-19-Patients.html,https://www.globenewswire.com/news-release/2020/03/24/2005534/0/en/Bioxytran-Licenses-Novel-Viral-Inhibitor-for-COVID-19-Patients.html,COVID-19,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Azmi,3/31/2020,,,
45,No,Actemra,Actemra,,Roche,Therapeutic,COVID-19,Protein-based (including monoclonal antibodies),Nonspecific anti-inflammatory and immunosuppressive drugs,Repurposed-Not Approved,Roche,United States,Ongoing,first approved anti-IL-6 receptor biologic available in both intravenous (IV) and subcutaneous (SC) formulations for the treatment of adult patients with moderate-to-severe active rheumatoid arthritis (RA).,,Phase 3,,,,,,,,,03/19/2020,,,,3,severe COVID-19 pneumonia,330,No,Not disclosed,Global,Early April 2020,,,,,"Roche is initiating a randomised, double-blind, placebo-controlled Phase III study (COVACTA) to evaluate the safety and efficacy of intravenous Actemra/RoActemra added to standard of care in adult patients hospitalised with severe COVID-19 pneumonia compared to placebo plus standard of care.",Azmi,4/1/2020,,,
45,Yes,Actemra,Actemra,,,https://www.roche.com/media/releases/med-cor-2020-03-19.htm,COVID-19,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
46,No,BCX4430,BCX4430,Galidesivir,Biocryst Pharma,Therapeutic,Other,Small molecule,Antiviral drugs-broad spectrum,New,NIAID;BARDA-NIH,United States,Ongoing,"Neucleoside analogue for Yellow Fever, broad spectrum.",,Phase 2,,,,,,,,,,,,,1,Yellow Fever,24,Yes,Not disclosed,Not disclosed,,,05/09/2019,,,,Azmi,4/3/2020,,,
46,Yes,Galidesivir,Galidesivir,,,http://ir.biocryst.com/news-releases/news-release-details/biocryst-completes-phase-1-clinical-trial-galidesivir,COVID-19,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
47,No,REGN3048-3051,REGN3048-3051,,Regeneron,Therapeutic,COVID-19,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
47,Yes,REGN3048-3051,REGN3048-3051,,,,COVID-19,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
48,No,SNG001,SNG001,,Synairgen Research,Therapeutic,COVID-19,Other,Other,Repurposed-Approved,Public funding through shares,United Kingdom,Ongoing,inhaled forumation of beta-1a interferon,,Phase 2,,,,,,,,03/18/2020,,MHRA and HRA approval,,,2,Covid-19,400,No,20,UK,03/18/2020,,,,,,Zain,04/02/2020,,,
48,Yes,https://www.synairgen.com/covid-19/,https://www.synairgen.com/covid-19/,,https://www.synairgen.com/covid-19/,https://www.synairgen.com/covid-19/,https://www.synairgen.com/covid-19/,https://www.synairgen.com/covid-19/,https://www.synairgen.com/covid-19/,https://www.synairgen.com/covid-19/,https://www.morningstar.co.uk/uk/news/AN_1585205934091906300/synairgen-raises-cash-to-go-towards-covid-19-drug-trial.aspx,https://www.synairgen.com/covid-19/,https://www.synairgen.com/covid-19/,https://www.synairgen.com/covid-19/,,https://www.synairgen.com/covid-19/,,,,,,,,https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001023-14/GB,,https://www.clinicaltrialsarena.com/news/cansino-synairgen-covid-19-trials/,,,https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001023-14/GB,https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001023-14/GB,https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001023-14/GB,https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001023-14/GB,https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001023-14/GB,https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001023-14/GB,https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001023-14/GB,,,,,,,,,,
49,No,AmnioBoost,AmnioBoost,,Lattice Biologics,Therapeutic,COVID-19,Other,Other,Repurposed-Approved,Lattice Biologics,United States,Ongoing,,,Phase 1,,,,,,,03/17/2020,,,,,,1,Covid-19,10,No,1,"Seattle, USA",03/17/2020,,,,,,Zain,04/02/2020,,,
49,Yes,https://www.biospace.com/article/releases/lattice-biologics-ltd-announces-initial-recruitment-of-patients-for-a-phase-1-clinical-trial-to-access-safety-and-efficacy-of-amnioboost-for-treatment-of-covid-19/,https://www.biospace.com/article/releases/lattice-biologics-ltd-announces-initial-recruitment-of-patients-for-a-phase-1-clinical-trial-to-access-safety-and-efficacy-of-amnioboost-for-treatment-of-covid-19/,,https://www.biospace.com/article/releases/lattice-biologics-ltd-announces-initial-recruitment-of-patients-for-a-phase-1-clinical-trial-to-access-safety-and-efficacy-of-amnioboost-for-treatment-of-covid-19/,https://www.biospace.com/article/releases/lattice-biologics-ltd-announces-initial-recruitment-of-patients-for-a-phase-1-clinical-trial-to-access-safety-and-efficacy-of-amnioboost-for-treatment-of-covid-19/,https://www.biospace.com/article/releases/lattice-biologics-ltd-announces-initial-recruitment-of-patients-for-a-phase-1-clinical-trial-to-access-safety-and-efficacy-of-amnioboost-for-treatment-of-covid-19/,https://www.biospace.com/article/releases/lattice-biologics-ltd-announces-initial-recruitment-of-patients-for-a-phase-1-clinical-trial-to-access-safety-and-efficacy-of-amnioboost-for-treatment-of-covid-19/,https://www.biospace.com/article/releases/lattice-biologics-ltd-announces-initial-recruitment-of-patients-for-a-phase-1-clinical-trial-to-access-safety-and-efficacy-of-amnioboost-for-treatment-of-covid-19/,https://www.biospace.com/article/releases/lattice-biologics-ltd-announces-initial-recruitment-of-patients-for-a-phase-1-clinical-trial-to-access-safety-and-efficacy-of-amnioboost-for-treatment-of-covid-19/,https://www.biospace.com/article/releases/lattice-biologics-ltd-announces-initial-recruitment-of-patients-for-a-phase-1-clinical-trial-to-access-safety-and-efficacy-of-amnioboost-for-treatment-of-covid-19/,https://www.biospace.com/article/releases/lattice-biologics-ltd-announces-initial-recruitment-of-patients-for-a-phase-1-clinical-trial-to-access-safety-and-efficacy-of-amnioboost-for-treatment-of-covid-19/,https://www.biospace.com/article/releases/lattice-biologics-ltd-announces-initial-recruitment-of-patients-for-a-phase-1-clinical-trial-to-access-safety-and-efficacy-of-amnioboost-for-treatment-of-covid-19/,,,https://www.businesswire.com/news/home/20200317005218/en/Lattice-Biologics-Ltd.-Announces-Initial-Recruitment-Patients,,,,,,,https://www.businesswire.com/news/home/20200317005218/en/Lattice-Biologics-Ltd.-Announces-Initial-Recruitment-Patients,,,,,,https://www.businesswire.com/news/home/20200317005218/en/Lattice-Biologics-Ltd.-Announces-Initial-Recruitment-Patients,https://www.businesswire.com/news/home/20200317005218/en/Lattice-Biologics-Ltd.-Announces-Initial-Recruitment-Patients,https://www.businesswire.com/news/home/20200317005218/en/Lattice-Biologics-Ltd.-Announces-Initial-Recruitment-Patients,https://www.businesswire.com/news/home/20200317005218/en/Lattice-Biologics-Ltd.-Announces-Initial-Recruitment-Patients,https://www.businesswire.com/news/home/20200317005218/en/Lattice-Biologics-Ltd.-Announces-Initial-Recruitment-Patients,https://www.businesswire.com/news/home/20200317005218/en/Lattice-Biologics-Ltd.-Announces-Initial-Recruitment-Patients,https://www.businesswire.com/news/home/20200317005218/en/Lattice-Biologics-Ltd.-Announces-Initial-Recruitment-Patients,,,,,,,,,,
50,No,,,,Enanta Pharmaceuticals,Therapeutic,COVID-19,Unknown,Antiviral drugs-not specified,New,Enanta Pharmaceuticals,United States,Ongoing,direct acting antiviral,,Discovery,,03/13/2020,,,,,,,,,,,,,,,,,,,,,,,Zain,04/02/2020,,,
50,Yes,,,,https://www.enanta.com/investors/news-releases/press-release/2020/Enanta-Pharmaceuticals-Announces-Efforts-to-Discover-a-Treatment-for-the-Novel-Coronavirus-Disease-COVID-19/default.aspx,https://www.enanta.com/investors/news-releases/press-release/2020/Enanta-Pharmaceuticals-Announces-Efforts-to-Discover-a-Treatment-for-the-Novel-Coronavirus-Disease-COVID-19/default.aspx,https://www.enanta.com/investors/news-releases/press-release/2020/Enanta-Pharmaceuticals-Announces-Efforts-to-Discover-a-Treatment-for-the-Novel-Coronavirus-Disease-COVID-19/default.aspx,https://www.enanta.com/investors/news-releases/press-release/2020/Enanta-Pharmaceuticals-Announces-Efforts-to-Discover-a-Treatment-for-the-Novel-Coronavirus-Disease-COVID-19/default.aspx,https://www.enanta.com/investors/news-releases/press-release/2020/Enanta-Pharmaceuticals-Announces-Efforts-to-Discover-a-Treatment-for-the-Novel-Coronavirus-Disease-COVID-19/default.aspx,https://www.enanta.com/investors/news-releases/press-release/2020/Enanta-Pharmaceuticals-Announces-Efforts-to-Discover-a-Treatment-for-the-Novel-Coronavirus-Disease-COVID-19/default.aspx,https://www.enanta.com/investors/news-releases/press-release/2020/Enanta-Pharmaceuticals-Announces-Efforts-to-Discover-a-Treatment-for-the-Novel-Coronavirus-Disease-COVID-19/default.aspx,https://www.enanta.com/investors/news-releases/press-release/2020/Enanta-Pharmaceuticals-Announces-Efforts-to-Discover-a-Treatment-for-the-Novel-Coronavirus-Disease-COVID-19/default.aspx,https://www.enanta.com/investors/news-releases/press-release/2020/Enanta-Pharmaceuticals-Announces-Efforts-to-Discover-a-Treatment-for-the-Novel-Coronavirus-Disease-COVID-19/default.aspx,https://www.enanta.com/investors/news-releases/press-release/2020/Enanta-Pharmaceuticals-Announces-Efforts-to-Discover-a-Treatment-for-the-Novel-Coronavirus-Disease-COVID-19/default.aspx,,https://www.enanta.com/investors/news-releases/press-release/2020/Enanta-Pharmaceuticals-Announces-Efforts-to-Discover-a-Treatment-for-the-Novel-Coronavirus-Disease-COVID-19/default.aspx,,https://www.enanta.com/investors/news-releases/press-release/2020/Enanta-Pharmaceuticals-Announces-Efforts-to-Discover-a-Treatment-for-the-Novel-Coronavirus-Disease-COVID-19/default.aspx,,,,,,,,,,,,,,,,,,,,,,,,,,,
51,No,VAAST,VAAST,Vaxart,Emergent BioSolutions,Therapeutic,COVID-19,Recombinant Vaccines,Other antiviral drugs,New,Emergent BioSolutions; Vaxart,USA,Ongoing,oral vaccine; recombinant adenovirus expressing HA; Non-Replicating Viral Vector,,Pre-Clinical Testing,,01/2020,16/03/2020,,,,06/2020,,,,,,1,COVID-19,,,,,,,,,,,Ekaterina Zvorykina,02.04.2020,,,
51,Yes,,,,,,COVID-19,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
52,No,LEAPS COVID-19,LEAPS COVID-19,,CEL-SCI,Therapeutic,COVID-19,Protein-based (including monoclonal antibodies),Antiviral drugs-broad spectrum,New,CEL-SCI; University of Georgia’s (UGA’s) Center for Vaccines,USA,Ongoing,immunotherapy,,Pre-Clinical Testing,,03/2020,23/03/2020,,,,,,,,,,1,COVID-19,,,,,,,,,,,Ekaterina Zvorykina,02.04.2020,,,
52,Yes,,,,,,COVID-19,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
53,No,Anti-SARS-CoV-2 polyclonal hyperimmune globulin (H-IG),Anti-SARS-CoV-2 polyclonal hyperimmune globulin (H-IG),TAK-888,Takeda Pharmaceutical Company,Therapeutic,COVID-19,Protein-based (including monoclonal antibodies),Antiviral drugs-broad spectrum,New,Takeda Pharmaceutical Company,Japan,Ongoing,a plasma-derived therapy,,Pre-Clinical Testing,,06/03/2020,,,,,,,,,,,1,COVID-19,,,,,,,,,,,Ekaterina Zvorykina,02.04.2020,,,
53,Yes,,,,,,COVID-19,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
54,No,Azithromycin-Hydroxychloroquine Combination,Azithromycin-Hydroxychloroquine Combination,,Pfizer,Therapeutic,COVID-19,Other,Antibiotics and antiparasitics,Repurposed-Not Approved,Pfizer,USA,Ongoing,,,Discovery,,,,,,,,,,,,,,,,,,,,,,,,,Ekaterina Zvorykina,02.04.2020,,,
54,Yes,,,,,,COVID-19,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
55,No,OT-101,OT-101,,Mateon Therapeutics,Therapeutic,COVID-19,protein based,antiviral drugs- broad spectrum,repurposed,,United States,ongoing,used to treat COVID-19 induced pneumonia,,phase 3,,,,,,,,,,,,,,,,,,,,,,,,Daisy,,,,,
55,Yes,,,,,,COVID-19,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
56,No,Remdesivir,Remdesivir,,Columbia University,Therapeutic,COVID-19,small molecule,antiviral- not specified,repurposed,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
56,Yes,hydroxycholoroquine (?),hydroxycholoroquine (?),,,,COVID-19,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
57,No,,,,Southwest Research Institute,Therapeutic,COVID-19,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
57,Yes,,,,,,COVID-19,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
58,No,,,,NanoViricides,Therapeutic,COVID-19,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
58,Yes,,,,,,COVID-19,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
59,No,modified anti-SARS-CoV-2 antibodies,modified anti-SARS-CoV-2 antibodies,,Vir Biotechnology,Prophylactic/Therapeutic,COVID-19,Protein-based (including monoclonal antibodies),Monoclonal antibodies,New,Wuxi Biologics; Biogen,,Ongoing,2 different modifications of one single clone of antibody originally developed against SARS-CoV-1; shown to act as both vaccine and therapeutic,,Pre-Clinical Testing,,,Started,,,,,,,,,,,,,,,,,,,,,,Yiwei Liu,4/1/2020,,,
59,Yes,https://www.statnews.com/2020/03/25/vir-biotechnology-reports-early-progress-in-antibody-treatment-for-covid-19/,https://www.statnews.com/2020/03/25/vir-biotechnology-reports-early-progress-in-antibody-treatment-for-covid-19/,,https://www.statnews.com/2020/03/25/vir-biotechnology-reports-early-progress-in-antibody-treatment-for-covid-19/,https://www.fiercebiotech.com/biotech/scangos-vir-biotechnology-to-test-covid-19-antibody-summer; https://www.biospace.com/article/vir-biotechnology-ids-2-monoclonal-antibodies-against-the-covid-19-coronavirus/,https://www.statnews.com/2020/03/25/vir-biotechnology-reports-early-progress-in-antibody-treatment-for-covid-19/,https://www.statnews.com/2020/03/25/vir-biotechnology-reports-early-progress-in-antibody-treatment-for-covid-19/,https://www.fiercebiotech.com/biotech/scangos-vir-biotechnology-to-test-covid-19-antibody-summer,https://www.fiercebiotech.com/biotech/scangos-vir-biotechnology-to-test-covid-19-antibody-summer,https://www.statnews.com/2020/03/25/vir-biotechnology-reports-early-progress-in-antibody-treatment-for-covid-19/,,https://www.statnews.com/2020/03/25/vir-biotechnology-reports-early-progress-in-antibody-treatment-for-covid-19/,https://www.fiercebiotech.com/biotech/scangos-vir-biotechnology-to-test-covid-19-antibody-summer,,https://www.statnews.com/2020/03/25/vir-biotechnology-reports-early-progress-in-antibody-treatment-for-covid-19/,,,https://www.statnews.com/2020/03/25/vir-biotechnology-reports-early-progress-in-antibody-treatment-for-covid-19/,,,,,,,,,,,,,,,,,,,,,,,,,,
60,No,siRNA against  SARS-CoV-1/2,siRNA against  SARS-CoV-1/2,,Alnylam; Vir Biotechnology,Therapeutic,COVID-19,Nucleic acid based therapies/vaccines,Antiviral drugs-antiretrovirals,New,,,Ongoing,350 candidates undergoing in vitro test,,Pre-Clinical Testing,,,Started,,,,,,,,,,,,,,,,,,,,,,Yiwei Liu,4/1/2020,,,
60,Yes,https://investors.alnylam.com/press-release?id=24656,https://investors.alnylam.com/press-release?id=24656,,https://investors.alnylam.com/press-release?id=24656,https://investors.alnylam.com/press-release?id=24656,https://investors.alnylam.com/press-release?id=24656,https://investors.alnylam.com/press-release?id=24656,https://investors.alnylam.com/press-release?id=24656,https://investors.alnylam.com/press-release?id=24656,,,https://investors.alnylam.com/press-release?id=24656,https://investors.alnylam.com/press-release?id=24656,,,,,https://investors.alnylam.com/press-release?id=24656,,,,,,,,,,,,,,,,,,,,,,,,,,
61,No,siRNA against  SARS-CoV-2,siRNA against  SARS-CoV-2,,Sirnaomics,Therapeutic,COVID-19,Nucleic acid based therapies/vaccines,Antiviral drugs-antiretrovirals,New,,,Ongoing,150 candidates under in vitro test,,Pre-Clinical Testing,,,Started,,,,,,,,,,,,,,,,,,,,,,Yiwei Liu,4/1/2020,,,
61,Yes,https://sirnaomics.com/news/sirnaomics-advances-rnai-based-prophylactics-and-therapeutics-to-battle-sari-caused-by-2019-ncov/,https://sirnaomics.com/news/sirnaomics-advances-rnai-based-prophylactics-and-therapeutics-to-battle-sari-caused-by-2019-ncov/,,https://sirnaomics.com/news/sirnaomics-advances-rnai-based-prophylactics-and-therapeutics-to-battle-sari-caused-by-2019-ncov/,,https://sirnaomics.com/news/sirnaomics-advances-rnai-based-prophylactics-and-therapeutics-to-battle-sari-caused-by-2019-ncov/,https://sirnaomics.com/news/sirnaomics-advances-rnai-based-prophylactics-and-therapeutics-to-battle-sari-caused-by-2019-ncov/,https://sirnaomics.com/news/sirnaomics-advances-rnai-based-prophylactics-and-therapeutics-to-battle-sari-caused-by-2019-ncov/,https://sirnaomics.com/news/sirnaomics-advances-rnai-based-prophylactics-and-therapeutics-to-battle-sari-caused-by-2019-ncov/,,,https://sirnaomics.com/news/sirnaomics-advances-rnai-based-prophylactics-and-therapeutics-to-battle-sari-caused-by-2019-ncov/,https://www.npr.org/sections/health-shots/2020/02/19/807338329/hunt-for-new-coronavirus-treatments-includes-gene-silencing-and-monoclonal-antib,,https://www.npr.org/sections/health-shots/2020/02/19/807338329/hunt-for-new-coronavirus-treatments-includes-gene-silencing-and-monoclonal-antib,,,https://www.npr.org/sections/health-shots/2020/02/19/807338329/hunt-for-new-coronavirus-treatments-includes-gene-silencing-and-monoclonal-antib,,,,,,,,,,,,,,,,,,,,,,,,,,
63,No,,,,AbCellera Biologics; Eli Lilly and Company,Therapeutic,COVID-19,Protein-based (including monoclonal antibodies),Monoclonal antibodies,New,Vaccine Research Centre - NIAID,Canada,Ongoing,Monoclonal antibodies; 500 antibody sequences isolated 03/12/2020,,Discovery,,03/05/2020,,,,,,,,,,,,,,,,,,,,,,,Gabbie,04/01/2020,,,
63,Yes,https://www.genengnews.com/news/to-develop-coronavirus-treatment-lilly-taps-abcellera-antibody-platform/,https://www.genengnews.com/news/to-develop-coronavirus-treatment-lilly-taps-abcellera-antibody-platform/,,,,COVID-19,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
64,No,BDB-001,BDB-001,,Beijing Defengrei Biotechnology,Therapeutic,COVID-19,Protein-based (including monoclonal antibodies),Monoclonal antibodies,Repurposed-Not Approved,Staidson (Beijing) Biopharmaceuticals Co. Ltd; InflaRx,China,Ongoing,Anti-C5a Antibody; Phase 2 trial number 2020L0003,,Phase 2,,Repurposed,SKIPPED,SKIPPED,SKIPPED,02/07/2020,SKIPPED,UNKNOWN,,,,,2,COVID-19,,No,,,,,,,,,Gabbie,04/01/2020,,,
64,Yes,https://www.clinicaltrialsarena.com/news/inflarx-covid-19-dosing-europe/,https://www.clinicaltrialsarena.com/news/inflarx-covid-19-dosing-europe/,,,,COVID-19,,,https://www.medrxiv.org/content/10.1101/2020.03.29.20041962v1.full.pdf,,,,,,https://www.bioworld.com/articles/433447-increasing-number-of-biopharma-drugs-target-covid-19-as-virus-spreads,,,,,,https://www.staidson.com/article/147.html,,https://www.medrxiv.org/content/10.1101/2020.03.29.20041962v1,,,,,https://www.medrxiv.org/content/10.1101/2020.03.29.20041962v1.full.pdf,,,,,,,,,,,,,,,,
65,No,siltuximab,siltuximab,Sylvant,EUSA Pharma,Therapeutic,COVID-19,Protein-based (including monoclonal antibodies),Monoclonal antibodies,Repurposed-Approved,Ergomed,England,Ongoing,Clinical trial NCT04322188 started but phase UNKNOWN,,,,Repurposed,SKIPPED,SKIPPED,SKIPPED,UNKNOWN,,,,,,,UNKNOWN,COVID-19,50,No,1,Papa Giovanni XXIII Hospital - Italy,03/19/2020,05/19/2020,,,,,Gabbie,04/02/2020,,,
65,Yes,https://www.clinicaltrialsarena.com/news/eusa-pharma-siltuximab-study-covid-19/,https://www.clinicaltrialsarena.com/news/eusa-pharma-siltuximab-study-covid-19/,,,,COVID-19,,,,,,,https://www.clinicaltrials.gov/ct2/show/record/NCT04322188,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
66,No,47D11,47D11,,Harbour Biomed,Therapeutic,COVID-19,Protein-based (including monoclonal antibodies),Monoclonal antibodies,New,Mount Sinai; Utrecht University; Eurasmus MC,China,Ongoing,Monoclonal antibodies,,Pre-Clinical Testing,,03/12/2020,03/12/2020,03/12/2020,,,,,,,,,,,,,,,,,,,,,Gabbie,04/02/2020,,,
66,Yes,https://www.biorxiv.org/content/10.1101/2020.03.11.987958v1.full.pdf+html,https://www.biorxiv.org/content/10.1101/2020.03.11.987958v1.full.pdf+html,,,,COVID-19,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
67,No,PolyTope mAb Therapy,PolyTope mAb Therapy,,ImmunoPrecise Antibodies Ltd; EVQLV,Therapeutic,COVID-19,Protein-based (including monoclonal antibodies),Monoclonal antibodies,New,,Canada,Ongoing,Monoclonal antibodies,,Pre-Clinical Testing,,03/12/2020,03/30/2020,,,,,,,,,,,,,,,,,,,,,,Rebecca Taylor,04/01/2020,,,
67,Yes,,,,https://www.proactiveinvestors.com/companies/news/916160/immunoprecise-antibodies-and-its-ai-collaborator-team-up-on-research-program-to-help-fight-coronavirus-916160.html,https://www.proactiveinvestors.com/companies/news/916160/immunoprecise-antibodies-and-its-ai-collaborator-team-up-on-research-program-to-help-fight-coronavirus-916160.html,COVID-19,https://www.thepharmaletter.com/article/immunoprecise-debuts-polytope-mab-therapy-to-tackle-coronavirus-pandemic,https://www.thepharmaletter.com/article/immunoprecise-debuts-polytope-mab-therapy-to-tackle-coronavirus-pandemic,https://www.thepharmaletter.com/article/immunoprecise-debuts-polytope-mab-therapy-to-tackle-coronavirus-pandemic,,https://www.thepharmaletter.com/article/immunoprecise-debuts-polytope-mab-therapy-to-tackle-coronavirus-pandemic,,https://www.proactiveinvestors.com/companies/news/916160/immunoprecise-antibodies-and-its-ai-collaborator-team-up-on-research-program-to-help-fight-coronavirus-916160.html,,https://www.immunoprecise.com/immunoprecises-artificial-intelligence-partner-evqlv-submits-first-panel-of-optimized-antibody-sequences-to-coronavirus-for-polytope-mab-therapy-program/,,https://www.immunoprecise.com/immunoprecise-announces-the-launch-of-polytope-mab-therapy-tm-to-tackle-coronavirus-pandemic/,https://www.immunoprecise.com/immunoprecises-artificial-intelligence-partner-evqlv-submits-first-panel-of-optimized-antibody-sequences-to-coronavirus-for-polytope-mab-therapy-program/,,,,,,,,,,,,,,,,,,,,,,,,,,
68,No,IFX-1,IFX-1,,InflaRx,Therapeutic,COVID-19,Protein-based (including monoclonal antibodies),Monoclonal antibodies,Repurposed-Approved,,Germany,Ongoing,Monoclonal antibodies,,Phase 1,,02/00/2020,03/00/2020,,,02/00/2020,03/00/2020,03/31/00,,,,,1,COVID19,2,No,1,China,03/31/20,,,,,,Rebecca Taylor,04/02/2020,,,
68,Yes,,,,https://www.inflarx.de/Home/Investors/Press-Releases/03-2020-InflaRx-Doses-First-Patient-in-Multicenter-Randomized-Clinical-Trial-in-Severe-Progressed-COVID-19-Pneumonia-in-Europe-upon-Receipt-of-Initial-Positive-Human-Data-with-InflaRx-s-anti-C5a-Technology.html,https://www.clinicaltrialsarena.com/news/inflarx-covid-19-dosing-europe/,COVID-19,https://www.nature.com/articles/d41587-020-00005-z,https://www.nature.com/articles/d41587-020-00005-z,https://www.inflarx.de/Home/Research---Development/Pipeline.html,,https://www.inflarx.de/Home/Investors/Press-Releases/03-2020-InflaRx-Doses-First-Patient-in-Multicenter-Randomized-Clinical-Trial-in-Severe-Progressed-COVID-19-Pneumonia-in-Europe-upon-Receipt-of-Initial-Positive-Human-Data-with-InflaRx-s-anti-C5a-Technology.html,https://www.clinicaltrialsarena.com/news/inflarx-covid-19-dosing-europe/,https://www.nature.com/articles/d41587-020-00005-z,,https://www.inflarx.de/Home/Investors/Press-Releases/03-2020-InflaRx-Doses-First-Patient-in-Multicenter-Randomized-Clinical-Trial-in-Severe-Progressed-COVID-19-Pneumonia-in-Europe-upon-Receipt-of-Initial-Positive-Human-Data-with-InflaRx-s-anti-C5a-Technology.html,,https://www.inflarx.de/Home/Investors/Press-Releases/02-2020-InflaRx-Announces-Positive-Initial-Data-from-Ongoing-Phase-IIa-Open-Label-Study-with-IFX-1-in-Patients-Suffering-from-Pyoderma-Gangraenosum-.html,https://www.inflarx.de/Home/Investors/Press-Releases/02-2020-InflaRx-Announces-Positive-Initial-Data-from-Ongoing-Phase-IIa-Open-Label-Study-with-IFX-1-in-Patients-Suffering-from-Pyoderma-Gangraenosum-.html,,,https://www.genengnews.com/virology/coronavirus/catching-up-to-coronavirus-top-60-treatments-in-development/,https://www.clinicaltrialsarena.com/news/inflarx-covid-19-dosing-europe/,https://www.nature.com/articles/d41587-020-00005-z,,,,,https://www.nature.com/articles/d41587-020-00005-z,https://www.nature.com/articles/d41587-020-00005-z,https://www.inflarx.de/Home/Investors/Press-Releases/03-2020-InflaRx-Doses-First-Patient-in-Multicenter-Randomized-Clinical-Trial-in-Severe-Progressed-COVID-19-Pneumonia-in-Europe-upon-Receipt-of-Initial-Positive-Human-Data-with-InflaRx-s-anti-C5a-Technology.html,https://www.nature.com/articles/d41587-020-00005-z,https://www.nature.com/articles/d41587-020-00005-z,https://www.nature.com/articles/d41587-020-00005-z,https://www.inflarx.de/Home/Investors/Press-Releases/03-2020-InflaRx-Doses-First-Patient-in-Multicenter-Randomized-Clinical-Trial-in-Severe-Progressed-COVID-19-Pneumonia-in-Europe-upon-Receipt-of-Initial-Positive-Human-Data-with-InflaRx-s-anti-C5a-Technology.html,,,,,,,04/03/2020,,,
69,No,Plitidepsin,Plitidepsin,Aplidin,Pharmamar,Therapeutic,COVID-19,Small molecule,Antiviral drugs-immunosupressive,Repurposed-Approved,CSIC,Spain,Ongoing,Anti-melanoma agent,,Phase 2,,02/00/2020,03/13/2020,,,,03/00/2020,04/00/2020,,,,,2,COVID 19,,No,,Spanish Hospitals,04/00/2020,,,,,,Rebecca Taylor,04/02/2020,,,
69,Yes,https://www.thepharmaletter.com/article/in-vitro-promise-of-aplidin-plitidepsin-for-covid-19-sends-pharmamar-upwards,https://www.thepharmaletter.com/article/in-vitro-promise-of-aplidin-plitidepsin-for-covid-19-sends-pharmamar-upwards,https://www.thepharmaletter.com/article/in-vitro-promise-of-aplidin-plitidepsin-for-covid-19-sends-pharmamar-upwards,https://www.thepharmaletter.com/article/in-vitro-promise-of-aplidin-plitidepsin-for-covid-19-sends-pharmamar-upwards,,COVID-19,https://www.drugbank.ca/drugs/DB04977,https://www.researchgate.net/publication/26280244_The_mechanism_of_action_of_plitidepsin,https://www.pharmamar.com/wp-content/uploads/2018/12/PR_Approval-APLIDIN-Australia.pdf,https://www.oncozine.com/plitidepsin-a-novel-anti-cancer-agent-possibly-active-against-covid18/,http://pharmamar.com/?lang=en,https://www.reuters.com/article/brief-pharma-mar-submits-phase-ii-clinic/brief-pharma-mar-submits-phase-ii-clinical-trial-of-aplidin-for-treatment-of-covid-19-to-spanish-medicines-agency-idUSFWN2BP1OB,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6505631/,,https://www.reuters.com/article/brief-pharma-mar-submits-phase-ii-clinic/brief-pharma-mar-submits-phase-ii-clinical-trial-of-aplidin-for-treatment-of-covid-19-to-spanish-medicines-agency-idUSFWN2BP1OB,,https://www.thepharmaletter.com/article/pharmamar-says-its-drug-aplidin-could-treat-covid-19,https://www.contractpharma.com/contents/view_breaking-news/2020-03-13/pharmamar-reports-positive-results-for-aplidin-against-coronavirus/,,,,,https://www.reuters.com/article/brief-pharma-mar-submits-phase-ii-clinic/brief-pharma-mar-submits-phase-ii-clinical-trial-of-aplidin-for-treatment-of-covid-19-to-spanish-medicines-agency-idUSFWN2BP1OB,,,,,,,,https://www.reuters.com/article/brief-pharma-mar-submits-phase-ii-clinic/brief-pharma-mar-submits-phase-ii-clinical-trial-of-aplidin-for-treatment-of-covid-19-to-spanish-medicines-agency-idUSFWN2BP1OB,,https://www.reuters.com/article/brief-pharma-mar-submits-phase-ii-clinic/brief-pharma-mar-submits-phase-ii-clinical-trial-of-aplidin-for-treatment-of-covid-19-to-spanish-medicines-agency-idUSFWN2BP1OB,https://www.reuters.com/article/brief-pharma-mar-submits-phase-ii-clinic/brief-pharma-mar-submits-phase-ii-clinical-trial-of-aplidin-for-treatment-of-covid-19-to-spanish-medicines-agency-idUSFWN2BP1OB,,,,,,,,,,
70,No,Ganovo + Ritonavir,Ganovo + Ritonavir,,Ascletis Pharma,Therapeutic,COVID-19,Small molecule,Protease Inhibitor,Repurposed-Approved,Shaoxing Government,China,Ongoing,Study patients discharged,,Phase 2,,,,,,01/25/2000,02/27/2020,03/10/2020,,,,,2,COVID19,3,No,,,,,,,,,Rebecca Taylor,04/02/2020,,,
70,Yes,,,,,,COVID-19,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
71,No,,,,Arcturus,,COVID-19,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
71,Yes,,,,,,COVID-19,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
72,No,Favipiravir,Favipiravir,Avigan; favilavir,Fujifilm; Peking University First Hospital,Therapeutic,COVID-19,Small molecule,Antiviral drugs-antiretrovirals,Repurposed-Approved,,Japan,Ongoing,Japan has stockpile of 2 million.,,Phase 3,,,,,,,,,3/31/2020,,,,Not Applicable,Covid-19,150,No,11,Anhui Medical University Affiliated First Hospital - Hefei - China; Guiqiang Wang - Beijing - China; Peking University First Hospital - Beijing - China; Cancer Hospital Union Hospital Tongji Medical College Huazhong University of Science and Technology - Wuhan - China; Ezhou Central Hospital - Wuhan - China; Huoshenshan Hospital of Wuhan - Wuhan - China; Jinyintan Hospital of Wuhan - Wuhan - China; Tongji Hospital of Huazhong University of Science and Technology - Wuhan - China; West Hospital Union Hospital Huazhong University of Science and Technology - Wuhan - China; Wuhan Pulmonary Hospital - Wuhan - China; Zhongnan Hospital of Wuhan University - Wuhan - China,3/8/2020,5/31/2020,5/31/2020,,,,Matthew,4/1/2020,,,
72,Yes,,,,https://www.fujifilm.com/jp/en/news/hq/3211,https://www.fujifilm.com/jp/en/news/hq/3211,https://www.fujifilm.com/jp/en/news/hq/3211,https://www.fujifilm.com/jp/en/news/hq/3211,https://www.fujifilm.com/jp/en/news/hq/3211,https://www.fujifilm.com/jp/en/news/hq/3211,,https://www.fujifilm.com/jp/en/news/hq/3211,https://www.fujifilm.com/jp/en/news/hq/3211,https://www.fujifilm.com/jp/en/news/hq/3211,,https://www.fujifilm.com/jp/en/news/hq/3211,,,,,,,,,https://www.fujifilm.com/jp/en/news/hq/3211,,,,https://clinicaltrials.gov/ct2/show/NCT04310228,https://clinicaltrials.gov/ct2/show/NCT04310228,https://clinicaltrials.gov/ct2/show/NCT04310228,https://clinicaltrials.gov/ct2/show/NCT04310228,,https://clinicaltrials.gov/ct2/show/NCT04310228,,https://clinicaltrials.gov/ct2/show/NCT04310228,https://clinicaltrials.gov/ct2/show/NCT04310228,,,,,,,,
73,No,,,,Zydus Cadila,Vaccine - Prophylactic,COVID-19,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
73,Yes,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
74,No,,,,Sinovac,Vaccine - Prophylactic,COVID-19,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
74,Yes,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
75,No,,Inactivated Vaccine,,Beijing Institute of Biological Products; Wuhan Institute of Biological Products,Vaccine - Prophylactic,COVID-19,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
75,Yes,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
76,No,,,,Codagenix; Serum Institute of India,Vaccine - Prophylactic,COVID-19,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
76,Yes,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
77,No,,,,DZIF - German Center for Infection Research,Vaccine - Prophylactic,COVID-19,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
77,Yes,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
78,No,,,,Greffex,Vaccine - Prophylactic,COVID-19,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
78,Yes,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
79,No,,,,AdaptVac,Vaccine - Prophylactic,COVID-19,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
79,Yes,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
80,No,,,,ExpreS2ion,Vaccine - Prophylactic,COVID-19,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
80,Yes,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
81,No,,,,WRAIR; USAMRIID,Vaccine - Prophylactic,COVID-19,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
81,Yes,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
82,No,,,,Vaxil Bio,Vaccine - Prophylactic,COVID-19,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
82,Yes,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
83,No,,,,Flow Pharma,Vaccine - Prophylactic,COVID-19,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
83,Yes,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
84,No,,,,Generex; EpiVax,Vaccine - Prophylactic,COVID-19,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
84,Yes,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
85,No,,,,EpiVax; University of Georgia,Vaccine - Prophylactic,COVID-19,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
85,Yes,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
86,No,,,,Heat Biologics; University of Miami,Vaccine - Prophylactic,COVID-19,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
86,Yes,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
87,No,,,,Baylor College of Medicine,Vaccine - Prophylactic,COVID-19,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
87,Yes,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
88,No,,,,iBio; CC-Pharming,Vaccine - Prophylactic,COVID-19,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
88,Yes,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
89,No,,,,VIDO-InterVac; University of Saskatchewan,Vaccine - Prophylactic,COVID-19,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
89,Yes,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
90,No,,,,OncoGen,Vaccine - Prophylactic,COVID-19,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
90,Yes,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
91,No,,,,Institute Pasteur; Themis; University of Pittsburg Center for Vaccine Research,Vaccine - Prophylactic,COVID-19,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
91,Yes,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
92,No,,,,Fudan University; Shanghai JiatTong University; RNACure Biopharma,Vaccine - Prophylactic,COVID-19,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
92,Yes,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
93,No,,,,China CDC; Tongji University; Stermina,Vaccine - Prophylactic,COVID-19,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
93,Yes,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
94,No,,,,Karolinska Institute,Vaccine - Prophylactic,COVID-19,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
94,Yes,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
95,No,,,,ReiThera,Vaccine - Prophylactic,COVID-19,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
95,Yes,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
96,No,,,,BioNet Asia,Vaccine - Prophylactic,COVID-19,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
96,Yes,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
97,No,,,,ImmunoPrecise,Vaccine - Prophylactic,COVID-19,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
97,Yes,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
98,No,,,,Doherty Institute,Vaccine - Prophylactic,COVID-19,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
98,Yes,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
99,No,,,,Tulane University,Vaccine - Prophylactic,COVID-19,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
99,Yes,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
100,No,,,,Hoth Therapeutics,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
100,Yes,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
101,No,,,,Dynavax; Clover,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
101,Yes,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
102,No,,STI-6991,,Sorrento Therapeutics,Vaccine - Prophylactic,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
102,Yes,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
103,No,,,VTP-500,Vaccitech,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
103,Yes,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
104,No,,,,Sanofi; Translate Bio,Vaccine - Prophylactic,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
104,Yes,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
105,No,,nebulized Ampion,,Ampio Pharmaceuticals,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
105,Yes,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
106,No,,Piclidenoson,,Can-Fite BioPharma Ltd.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
106,Yes,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
107,No,,Fingolimod,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
107,Yes,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
108,No,,BDB-1,,InflaRx N.V.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
108,Yes,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
109,No,,remestemcel-L,Ryoncil,Mesoblast Limited,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
109,Yes,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
110,No,,tocilizumab,Actemvra,Rogers Corporation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
110,Yes,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
111,No,,Diammonium,,Sino Biopharmaceuticals,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
111,Yes,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
112,No,,Dantonic,T89,Tasly Pharmaceuticals,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
112,Yes,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
113,No,,Monoclonal Antibodies,,AztraZeneca PLC,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
113,Yes,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
114,No,,Monoclonal Antibodies,,Celtrion,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
114,Yes,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
115,No,,Monoclonal Antibodies,,Dyadic International,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
115,Yes,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
116,No,,mabvrilmumab,,Kiniksa Pharmaceuticals,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
116,Yes,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
117,No,,,,Vir; Generation Bio,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
117,Yes,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
118,No,,,,Vir; WuXi Biologics,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
118,Yes,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
119,No,,,,Vir; Xencor,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
119,Yes,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
120,No,,,,Alnylam; Vir,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
120,Yes,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
121,No,,TAK-888,Plasma Immunoglobulins,Takeda,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
121,Yes,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
122,No,,,Plasma Immunoglobulins,CERS,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
122,Yes,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
123,No,,,Plasma Immunoglobulins,Grifols,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
123,Yes,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
124,No,,,Plasma Immunoglobulins,Mount Sinai Health System,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
124,Yes,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
125,No,,,Plasma Immunoglobulins,China National Biotec,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
125,Yes,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
126,No,,,,NeurRx; Relief Therapeutics,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
126,Yes,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
127,No,,STI-4398,,Sorrento Therapeutics inc.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
127,Yes,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
128,No,,,,University of Life,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
128,Yes,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
129,No,,,INOpulse,Bellepheron Therapeutics Inc.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
129,Yes,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
130,No,,,CytoSorb,CytoSorbents Corporation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
130,Yes,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
131,No,,,SNX-5542,Esanex,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
131,Yes,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
132,No,,crofelemer,Mytesi,Jaguar Health,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
132,Yes,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
133,No,,,,Leibniz Institute,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
133,Yes,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
134,No,,,,Allergan,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
134,Yes,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
135,No,,,,OncoImmune,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
135,Yes,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
136,No,,,,Pulmotect,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
136,Yes,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
137,No,,,,Asan Medical Center,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
137,Yes,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
138,No,,,,Digestive Disease Research Institute,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
138,Yes,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
139,No,,,,Doi Yohei,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
139,Yes,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
140,No,,,,Fondation Mediterranee Infection,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
140,Yes,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
141,No,,,,INSERM,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
141,Yes,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
142,No,,,,Massachusetts General Hospital,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
142,Yes,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
143,No,,,,National Cancer Institute,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
143,Yes,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
144,No,,,,"National Institute or Respiratory Diseases, Mexico",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
144,Yes,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
145,No,,,,Rajavithi Hospital,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
145,Yes,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
146,No,,,,Shahid Beheshti Univeristy of Medical Sciences,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
146,Yes,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
147,No,,,,Synairgen Research Limited,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
147,Yes,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
148,No,,,,Tehran University of Medical Sciences,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
148,Yes,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
149,No,,,,Tokue Yutaka,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
149,Yes,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
150,No,,,,Beijing Chaoyang Hospital; Capital Medical University,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
150,Yes,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
151,No,,,,Beijing You'an Hospital; Capital Medical University,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
151,Yes,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
152,No,,,,Capital Medical University,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
152,Yes,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
153,No,,,,Central South Hospital of Wuhan University,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
153,Yes,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
154,No,,,,Chinese PLA General Hospital,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
154,Yes,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
155,No,,,,Chongqing Public Health Medical Center,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
155,Yes,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
156,No,,,,Foshan First People's Hospital,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
156,Yes,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
157,No,,,,Health commission of Heilongjiang province,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
157,Yes,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
158,No,,azvudine,,Henan Provincial People's Hospital,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
158,Yes,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
159,No,,,,Huilan Zhang,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
159,Yes,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
160,No,,,,Hwa Mei Hospital; University of Chinese Academy of Sciences,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
160,Yes,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
161,No,,,,Jingzhou First People's Hospital,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
161,Yes,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
162,No,,,,Peking Union Medical College Hospital,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
162,Yes,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
163,No,,,,Peking University First Hospital,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
163,Yes,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
164,No,,,,People's Hospital of Guangshan County,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
164,Yes,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
165,No,,,,Qazvin University of Medical Sciences,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
165,Yes,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
166,No,,,,Qilu Hospital of Shandong University,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
166,Yes,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
167,No,,,,Renmin Hospital of Wuhan University,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
167,Yes,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
168,No,,,,Second Affiliated Hospital of Wenzhou Medical University,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
168,Yes,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
169,No,,,,Shahid Beheshti University of Medical Sciences,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
169,Yes,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
170,No,,,,Shanghai Public Health Clinical Center,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
170,Yes,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
171,No,,,,Southeast University - China,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
171,Yes,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
172,No,,,,Tang-Du Hospital,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
172,Yes,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
173,No,,,,The First Affiliated Hospital of Fujian Medical University,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
173,Yes,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
174,No,,,,Tongji Hospital,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
174,Yes,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
175,No,,,,Xijing Hospital,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
175,Yes,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
176,No,,,,ZhiYong Peng,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
176,Yes,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
177,No,,,,Peter Doherty Institute for Infection and Immunity,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
177,Yes,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
178,No,,,,Celularity Inc.; Sorrento Therapeutics Inc.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
178,Yes,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
179,No,,,STI-4920; CMAB020,Sorrento Therapeutics Inc.; Mabpharm Limited,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
179,Yes,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
180,No,,,,SmartPharm Therapeutics Inc.; Sorrento Therapeutics Inc.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
180,Yes,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
181,No,,,,Celltrion,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
181,Yes,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
182,No,,,,Kamada,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
182,Yes,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
183,No,,,,Swiftscale Biologics,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
183,Yes,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
184,No,,,,Erasmus MC; Utrecth University,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
184,Yes,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
185,No,,,Prezcobix,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
185,Yes,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
186,No,,,Arbidol,Pharmstandard,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
186,Yes,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
187,No,,,Xofluza,Roche,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
187,Yes,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
188,No,,,PLX cell product,Pluristem,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
188,Yes,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
189,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
189,Yes,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
190,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
190,Yes,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
191,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
191,Yes,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
192,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
192,Yes,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
193,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
193,Yes,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
194,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
194,Yes,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
195,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
195,Yes,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
196,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
196,Yes,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
197,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
197,Yes,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
198,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
198,Yes,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
199,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
199,Yes,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
200,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
200,Yes,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
201,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
201,Yes,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
202,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
202,Yes,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
203,No,,,,,,COVID-19,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
203,Yes,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,Legend,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,Sponsor or reputably sourced information,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,Social Media or disputablly sourced information,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,Our best guesses or highly uncertain source of information (highly uncertain),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,NOTES/COMMENTS,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,Data Sources,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,Manual data entry from press releases; media articles or social media,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,clinicaltrials.gov API,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,Functionality Needed and Nice-to-haves,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,Necessary,,Visitors can provide updates/corrections/feedback,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,Necessary,,Non-technical admin can make updates,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,Nice-to-have,,Visualizations of timelines; both to-date and projections,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,Nice-to-have,,"""In the news"": news items pulled automatically from google news through keywords or user-submitted; either by asset or one big rolling list",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,Nice-to-have,,Chart pulling from Clinicaltrials.gov showing upcoming; recruiting; ongoing; completed studies on Coronavirus,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,Nice-to-have,,Map pulling from ongoing clinical study site locations (column T) to show which hospitals are actively conducting research,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,Nice-to-have,,Message board with moderation functionality,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,Nice-to-have,,"""Claim this asset"" for sponsors to provide their own updates",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,Nice-to-have,,Pop-up explainers for milestones.  I've added descriptors in the notes for each milestone in excel,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,Nice-to-have,,Stock price information for public company sponsors,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,Explanation; Disclaimers and Footer Information,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,Please note that while we have tried to capture information from the best sources and stay as up-to-date as possible; the information below might not be accurate and should not considered offical or definitive information ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,The milestone are ordered in a sequence that approximates the natural progression of vaccine development; but certain activities can be done in parallel or out-of-order or can be skipped entirely,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,Any estimates for when milestones will be started or completed are estimates that should not be considered offical or definitive information; unless we indicate the information came directly from the sponsor.  Even then please note these still estimates and delays are common in clinical development.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,At any point in the process; drug development is likely to fail.  Estimates of success rates from Phase 1 to Regulatory Approval range from 3.5% to 15% depending on the therapeutic area and the source of the estimates. ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,This website was developed by <insert contributors names>,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,Inspired by Effective Altruism,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,Potential Partner Organizations or sources of information,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,CEPI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,Sabin Vaccine Institute,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,John Hopkins Center for Health Security,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,Gavi,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,Version Control,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,3/18/2020,,Mats Olsen Drafted V1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,Current Data Entry Assignement,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,Version,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,